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The prevalence of allergic asthma, allergic rhinitis and atopic dermatitis has been 
increasing worldwide in recent decades. The dust mite Blomia tropicalis is one of the 
main triggering factors for allergic diseases. This mite species is affecting 
approximately one billion people in the tropics, subtropics and certain temperate 
regions. Allergen-specific immunotherapy is currently the only means to alter the 
underlying mechanisms that lead to cure the allergic diseases. Several preclinical 
studies and clinical trials have suggested a possible role of lactobacilli in the 
prevention and treatment of allergic diseases. Lactobacilli are generally regarded as 
safe for oral consumption. They possess distinct adjuvant properties and exert 
differential immunomodulatory effects on dendritic cells (DCs). The use of 
lactobacilli as live vectors for oral delivery is a desirable strategy for the development 
of oral vaccine for allergy. 
 
The aim of this study is to evaluate the immunomodulatory effects of Lactobacillus 
plantarum NC8 and Lactobacillus rhamnosus GG on DCs in vitro and in murine 
allergy models in vivo. The major allergen from Blomia tropicalis, Blo t 5, was 
expressed in both Lactobacillus strains intracellularly using the pSIP412 expression 
vector. Both recombinant Lactobacillus plantarum NC8 (rLp) and recombinant 
Lactobacillus rhamnosus GG (rLGG) could induce the maturation of bone marrow-
derived dendritic cells (BMDCs) as measured by the upregulation of surface markers 
 ix
and cytokine production. Furthermore, recombinant lactobacilli-pulsed BMDCs 
effectively activated a Blo t 5-specific T cell line. However, both recombinant 
lactobacilli exhibited differential modulatory effects on murine DCs as reflected by 
their differential cytokine production profiles.  
 
The in vivo evaluation focused on the immunogenicity of recombinant lactobacilli 
and their protective effects against allergen-specific Th2 immune responses. Both 
recombinant lactobacilli-fed naive mice could elicit Blo t 5-specific B and T cell 
responses. In the prophylactic model, mice pre-fed with either recombinant 
Lactobacillus strain were protected against Blo t 5 sensitisation by intraperitoneal 
injection with Blo t 5 in alum as shown by the attenuation of Blo t 5-specific IgE, the 
concomitant enhancement of protective Blo t 5-specific IgG2c, and the suppression of 
Th2 cytokines production by Blo t 5-stimulated splenocytes and cells from mesenteric 
lymph nodes (MLN). In the therapeutic model, mice were adoptively transferred with 
Blo t 5-specific Th2 cell line and fed with recombinant lactobacilli followed by the 
intranasal challenge with Blo t 5. Recombinant Lactobacillus rhamnosus GG-fed 
mice showed attenuated allergic airway inflammation as manifested by the reduction 
of the signature cell type for allergic inflammation, eosinophils, in the 
bronchoalveolar lavage fluids.  
 
In summary, recombinant lactobacilli expressing respectable levels of Blo t 5 protein 
have been generated and comparatively evaluated by in vitro and in vivo studies. Both 
recombinant lactobacilli were effective in the prevention of allergen sensitisation 
 x
despite their respective differential immunomodulatory properties in vitro. 
Lactobacillus rhamnosus GG was more effective than the recombinant Lactobacillus 
plantarum NC8 in the suppression of established airway inflammation. Further 
studies are required to address the underlying mechanisms and the clinical application 
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The term “allergy”, originally coined by Clemens von Pirquet, implies deviation 
from the original state (von Pirquet C, 1906). However, this terminology has since 
been redefined and used to describe T helper 2 (Th2)-associated immune reactions 
to common environmental proteins, known as allergens (Kay AB, 2006). 
Allergen-specific Th2 cells play a central role in the development of allergic 
diseases such as asthma, rhinitis and atopic eczema. Over the past 25 years, the 
prevalence and severity of allergic diseases have reached epidemic proportions in 
the developed countries (Holgate ST, 1999). Allergic diseases are considered a 
major health problem that afflicts about 10% to 40% of the world’s populations. 
Billions of dollars of expenditures are being spent in the medical and health care 
related industry worldwide (ISAAC, 1998; Weiss KB, 2000). Allergic asthma is 
the most important allergic disease that is also being regarded as a common and 
serious respiratory disease worldwide.  
 
1.1 House dust mite allergy-associated allergic diseases 
Several reports and epidemiological studies have demonstrated that house dust 
mites (HDM) represent the most ubiquitous and important major indoor 
aeroallergens associated with allergic diseases such as allergic asthma, allergic 
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rhinitis and atopic eczema (Platts-Mills, 1989; Holgate ST, 1999; Ulrik CS, 2000; 
Lau S, 2000; Arlian LG, 2001). They play a crucial role in the pathogenesis of the 
allergic diseases.  
 
Dermatophagoides pteronyssinus (Der p), Blomia tropicalis (Blo t), 
Dermatophagoides farinae (Der f) and Euroglyphus maynei (Eur m) are the most 
prevalent HDM species found in the world. The distribution of these domestic 
mite species and allergens vary geographically (Arlian LG, 2002). Humidity is the 
key factor for the survival of mite and their prevalence. Among them, Der p 
allergens are the main triggering factors for allergic diseases worldwide (Arlian 
LG, 1992; Thomas WR, 2002), whereas Blo t allergens are the main allergic 
triggering factors in the tropical and subtropical countries (Fernández-Caldas E, 
1990; Puerta Llerena L, 1991; Chew FT, 1999, Kuo IC, 1999; Sanchez-Borges M, 
2003; Puccio FA, 2004; Sun BQ, 2004; Yu MK, 2008). The co-existence of both 
Der p and Blo t allergens as well as the dual-sensitisation of atopic individual to 
both allergens are commonly found in the tropical and subtropical countries 
(Zhang L, 1997; Chew FT, 1999). Strikingly, the sensitisation of allergic patients 
to Blo t allergens is relatively common in Singapore and other tropical countries 
as compared to Der p allergens (Chew FT, 1999; Mariana A, 2000; Yeoh SM, 
2003; Yi FC, 2004; Chua KY, 2007). Based on the immunochemical and 
cross-reactivity studies, Blo t allergens have been shown to have a relatively low 
to moderate cross-reactivity with Der p allergens (Chew FT, 1999). Therefore, Blo 
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t allergens were suggested to be included in the routine diagnostic testing for the 
evaluation of allergic diseases as well as the development of new preventive and 
therapeutic strategies in the tropical and subtropical countries (Chew FT, 1999; 
Puccio FA, 2004). 
 
Approximately 1 billion people worldwide were reported to be sensitised to 
Blomia tropicalis according to the World Allergy Organization Congress, which 
was held in December 2007 in Bangkok. Blomia tropicalis is the most prevalent 
house dust mite species which is responsible for the provocation of allergy in 
tropical, subtropical and certain temperate regions with long and humid summer 
worldwide. In Singapore, Blomia tropicalis mite allergens trigger about 60% to 
70% of allergic diseases such as asthma, allergic rhinitis and eczema, particularly 
in young allergic children. Blomia tropicalis group 5 allergen (Blo t 5) has been 
identified as the predominant allergen of Blomia tropicalis which sensitised up to 
90% of the mite allergic patients (Arruda LK, 1995; Kuo IC, 2003; Manolio TA, 
2003; Yeoh SM, 2003). Thus, there is a great demand in the development of 
vaccine for the management of Blo t 5-associated allergic diseases in these 
geographical regions. In view of the clinical importance of Blo t 5 allergen, it has 
been targeted as a candidate for vaccine development for the prevention and 
treatment of HDM-related allergic diseases.  
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1.1.1 Blomia tropicalis mite allergens 
Blomia tropicalis mite was first described by van Bronswijk in 1974. This 
globular-shaped storage mite (Figure 1.1) is the most abundant non-pyroglyphid 
mite in the house dust of the tropical and subtropical countries where both the 
mean temperature (28ºC) and mean relative humidity (85%) are high. Its scientific 









Mite allergens are biochemically active molecules present in mite bodies, secreta 
and excreta (Tovey ER, 1981; Arlian LG, 1987). Allergenicity studies of Blomia 
tropicalis have revealed the existence of more than 20 Blo t allergens. To date, 
seven Blo t allergens were published with known complementary 
deoxyribonucleic acid (cDNA) sequences, whereas another three Blo t allergens 
were unpublished but submitted to the International Union of Immunological 
Societies (Yi FC, 2006).  
 




















Figure 1.1 Frontal view of Blomia tropicalis enlarged 200 times. 
(Adapted from Fernández-Caldas E, Lockey RF. Blomia tropicalis, a mite whose 
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Blo t 5 cDNA (see Appendix 1) contains a 402-basepair (bp) open reading frame 
that encodes for a 17-amino acid (aa) signal peptide followed by the mature 
protein with 117 amino acids (Arruda LK, 1995). Its calculated molecular weight 
(MW) and theoretical isoelectric point (pI) value are 13.89 kilo Daltons (kDa) and 
5.15, respectively. The total numbers of positively (Arg + Lys) and negatively 
(Asp + Glu) charged residues of Blo t 5 are 18 (15.4%) and 26 (22.2%). The 
extinction coefficient is low due to the lack of the tryptophan residue in Blo t 5. In 
addition, it has one cysteine residue and one potential N-linked glycosylation site. 
It is first cloned and expressed in Escherichia coli (E. coli) as a fusion protein 
with gluthathione-S-transferase (GST). Despite its 43% amino acid sequence 
identity to Der p 5 (see Appendix 2), the immunologlobulin E (IgE) 
cross-reactivity between Blo t 5 and Der p 5 is low (Arruda LK, 1995; Chew FT, 
1999; Kuo IC, 2003). Even though the three-dimensional (3D) structure of Blo t 5 
allergen (see Appendix 2) has been resolved by Nuclear Magnetic Resonance 
(NMR) (Naik MT, 2008), yet the biological function of Blo t 5 remains unknown.  
 
1.1.2 Immunological mechanisms 
HDM-associated type I allergic diseases have been regarded as an IgE-mediated 
hypersensitivity. They are the main source of ubiquitous indoor allergens that 
cause IgE-mediated sensitisation among patients with allergic rhinitis, asthma and 
atopic skin dermatitis (Platts-Mills, 1989; Platts-Mills, 1992). The mechanism 
underlying the type I allergic diseases as shown in Figure 1.2 involves a complex 
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series of events (Hawrylowicz CM, 2005; Larché M, 2006; Galli SJ, 2008). 
 
Upon the inhalation and exposure of allergen, antigen presenting cells (APC) 
uptake and present the processed allergen to Th cells in the context of major 
histocompatibility complex (MHC) class II molecules (Mudde GC, 1990). The 
naïve CD4+ T cells are then differentiated into Th2 phenotype. The differentiation 
and clonal expansion of allergen-specific Th2 cells lead to further production of 
Th2 cytokines such as interleukin (IL)-4, IL-5, IL-9, IL-13 and so forth. These 
Th2 cytokines are critical for the development of humoral immune response, IgE 
class switching as well as the pathogenesis of allergic diseases (Kips JC, 2001; 
Fallon PG, 2002; Georas SN, 2005). IL-4 promotes the differentiation of 
allergen-specific Th2 cells, whereas IL-5 leads to the activation and infiltration of 
eosinophils (Sanderson CJ, 1992). Eosinophils are capable of secreting cytokines 
such as IL-4, IL-5 and IL-6. These cytokines may act as an autocrine to increase 
the eosinophils survival and enhance tissue inflammation. On the other hand, 
IL-13 has been shown to play a role in the mucus hypersecretion, vascular 
permeability, smooth-muscle contraction and airway hyperresponsiveness (Grünig 
G,, 1998; Wills-Karp M, 1998; Montaner LJ, 1999; Corry DB, 1999; Wynn TA, 
2003; Wills-Karp M, 2004). In addition, IL-9 can act on many cell types in asthma, 
including T cells, B cells, mast cells, eosinophils, neutrophils and epithelial cells. 
 
 






Figure 1.2 Allergic Mechanisms. In pre-disposed individuals, initial exposure(s) 
to allergen leads to the activation of allergen-specific T helper 2 (Th2) cells and 
IgE synthesis, which is known as allergic sensitisation. Subsequent exposures to 
allergen cause inflammatory-cell recruitment and activation and mediator release, 
which are responsible for early (acute) allergic responses (EARs) and late allergic 
responses (LARs). In the EAR, within minutes of contact with allergen, 
IgE-sensitised mast cells degranulate, releasing both pre-formed and newly 
synthesised mediators in sensitised individuals. These include histamine, 
leukotrienes and cytokines, which promote vascular permeability, smooth-muscle 
contraction and mucus production. Chemokines released by mast cells and other 
cell types direct recruitment of inflammatory cells that contribute to the LAR, 
which is characterised by an influx of eosinophils and Th2 cells. Eosinophils 
release an array of pro-inflammatory mediators, including leukotrienes and basic 
proteins (cationic proteins, eosinophil peroxidase, major basic protein and 
eosinophil-derived neurotoxin), and they might be an important source of 
interleukin-3 (IL-3), IL-5, IL-13 and granulocyte/macrophage colony-stimulating 
factor. Neuropeptides are also proposed to contribute to the pathophysiology of 
allergic symptoms. TCR, T-cell receptor. 
 
(Adapted from Hawrylowicz CM, O'Garra A. Potential role of 
interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev 
Immunol. 2005. 5:271-83) 
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One of the hallmarks of atopic diseases is the production of allergen-specific IgE. 
IL-4 and IL-13 favour the production of allergen-specific IgE by B cells. Other 
cytokines such as IL-5, IL-6 and IL-9 can enhance the IgE production, whereas 
interferon (IFN)-γ and IL-12 are shown to inhibit the isotype switching and 
production of IgE. The cross-linking of IgE-FcεRI complexes by allergen leads to 
the activation and degranulation of mast cells. The release of vasoactive amines 
such as histamine, lipid mediators such as prostaglandin D, platelet-activating 
factor, leukotriene C4 (LTC4), LTD4, LTE4 as well as chemokines such as 
CXC-chemokine ligand 8 (CXCL8), CXCL10, CC-chemokine ligand 2 (CCL2), 
CCL4 and CCL5 contribute to the immediate symptoms of allergic diseases (Kay 
AB, 2001; Kalesnikoff J, 2001; Gould HJ, 2003). The late phase of allergic 
responses is characterised by the additional recruitment and activation of 
eosinophils and Th2 cells at the site of allergen challenge. 
 
1.1.3 Current preventive measures and therapeutic approaches 
To date, the preventive measures and therapies available for the HDM-associated 
allergic diseases include allergen avoidance, pharmacotherapy and 
allergen-specific immunotherapy (SIT).  
 
House dust mite avoidance measures, which were proposed by Storm van 
Leeuwen in 1925, are widely recommended as part of a secondary and tertiary 
prevention strategy for allergic disease. There is some evidence to support the 
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preventive effect of house dust mite allergen avoidance before sensitisation occurs 
(Arshad SH, 2003). However, recent meta-analysis of published trials has reached 
a conclusion that there are no statistically significant benefits of dust mite 
avoidance interventions for allergic patients. It may not prevent the onset of 
allergic diseases in high-risk children (Arshad SH, 2004; Marks GB, 2006). 
 
Current treatments for allergy and asthma are mainly based on pharmacotherapy. 
Antihistamines, corticosteroids, bronchodilators and many more are commonly 
used as medication for the treatment of mite allergy. These drugs effectively 
provide short-term relief to the patients. However, they do not suppress the rise 
caused by allergen exposure. Although larger doses of drugs are given, there is 
still no effect on the serum IgE in patients. Patients are required to take these 
drugs for life. It might be a burden for some families who face financial 
difficulties. As a result, patients’ compliance and the side-effects of these drugs 
have become the major concerns in the treatment of allergic diseases. There is an 
impaired quality of life despite the adequate pharmacological treatment. 
 
In fact, allergen-specific immunotherapy (SIT) represents the only aetiology 
treatment for allergic diseases, by providing allergen-specific and long-term 
protective immune responses. It was first introduced by Leonard Noon in the 
prevention of grass pollen allergy that the injection of small doses of pollen 
extract could induce antitoxin and ameliorate the disease (Noon L, 1911). SIT may 
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prevent the onset of new sensitisations in children with respiratory symptoms 
mono-sensitised to house dust mite (Pagno GB, 2001). This immune-modifying 
therapy induced immunological tolerance and the production of blocking 
antibodies through repeated exposure to allergens. However, this approach has 
potential systemic side effects and life-threatening anaphylactic responses. It may 
potentially induce new IgE reactivity to other components in the extracts. Besides, 
the long duration of treatment and the route of administration limit the patients’ 
compliance. The standardisation of allergen extracts due to the batch variation is 
yet another major issue.  
 
Conventional SIT involves repeated administration of the sensitising allergen 
extracts by subcutaneous injection or more recently, by sublingual route. 
Subcutaneous injection (SCIT) involves the regular subcutaneous injection of 
allergen extracts or recombinant allergens using incremental regimes. Most 
regimes used consists of a build-up phase (weekly injections) followed by a 
maintenance phase (monthly injections). Although the duration of the regime is 
long, the tolerance can last for several years once it is induced. It has been shown 
to be efficacious for the treatment of type I allergy (Werfel T, 2006; Bussmann C, 
2007). On the other hand, sublingual immunotherapy (SLIT) is now accepted as a 
valuable alternative to SCIT for the treatment of allergic diseases. Based on the 
ground of safety, long-lasting efficacy, compliance and ease of applicability, it has 
been so far favoured in human use especially in children (Rienzo VD, 2003; 
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Rienzo VD, 2005; Passalacqua G, 2006; Pajno GB, 2007; Passalacqua G, 2007). 
Despite a few promising clinical studies showing the efficacy in the treatment of 
HDM-associated allergic diseases, the underlying immunological mechanisms of 
SLIT have only begun to be investigated which includes the time of application, 
duration of treatment, dosages and formulation of the allergens.  
 
Furthermore, the application of modern bioinformatics tools and elucidation of the 
three-dimensional structure of major allergens have led to the allergen 
identification and sequencing, production of recombinant allergens, identification 
of B-cell and T-cell epitopes, as well as the tertiary structural analysis of allergen 
molecules for allergen research. Site-directed mutagenesis, expression of 
polypeptide fragments and introduction of single amino acid approaches have 
been commonly used to generate hypoallergens with reduced IgE reactivity and 
allergenicity while retaining their structural requirements for T-cell reactivity and 
induction of blocking antibodies against natural allergens. These hypoallergens are 
safer and more effective potential candidates for allergen-specific immunotherapy. 
Structurally modified hypoallergens have been produced for house dust mite 
(Smith AM, 1996; Takai T, 1997; Takai T, 2000, Yasuhara T, 2001), pollen, venom, 
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Moreover, DNA vaccination with plasmid DNA encoding allergen preferentially 
prime allergen-specific T helper 1 (Th1) immune response and has been 
postulated to potentially down-regulate the Th2 responses. The protective effects 
of DNA vaccine against HDM allergy have been demonstrated in murine studies 
with reduced infiltration of inflammatory cells, allergen-specific IgE and Th2 
cytokines (Hsu CH, 1996; Jarman ER, 2004; Kim N, 2006). Thus, DNA 
vaccination is an alternative option for the prevention and reversal of 
Th2-mediated allergic hypersensitivity (Chua KY, 2006).  
 
 
1.2 The history and definition of probiotics 
The term “probiotics” was derived from the Greek and literally translated as 
“for-life”. In the beginning of the last century, Eli Metchnikoff, the Russian-born 
Nobel Prize recipient working at the Pasteur Institute first suggested that “the 
dependence of the intestinal microbes on the food makes it possible to adopt 
measures to modify the flora in our bodies and to replace the harmful microbes by 
useful microbes” (Metchnikoff E, 1907). Metchnikoff was the first to describe the 
therapeutic potential of lactic acid bacteria (LAB) (Metchnikoff E, 1910). He 
proposed that LAB could minimise, or prevent, the harmful effects of putrefactive 
microbes that cause gastrointestinal (GI) disease. Decreased number of “bifid” 
bacteria was found in the faeces of children with diarrhoea as compared to healthy 
children (Tissier H, 1906). Thereby, Henry Tissier hypothesised that 
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administration of these “bifid” bacteria to children with diarrhoea could help them 
in restoring a healthy gut flora. Yet, the word “probiotics” was not coined until the 
later past of the last century.  
 
The definition of probiotics has evolved through the years. In 1974, it was 
described as “Organisms and substances which contribute to intestinal microbial 
balance” (Parker RB, 1974). In 1989, it was redefined as “A live microbial feed 
supplement which beneficially affects the host animal by improving its intestinal 
balance” (Fuller R, 1989). A few years later, a similar definition was also 
proposed that “A viable mono or mixed culture of bacteria which, when applied to 
animal or man, beneficially affects the host by improving the properties of the 
indigenous flora” (Havenaar R, 1992). More recently, Schrezenmeir and de Vrese 
redefined it as “A preparation of or a product containing viable, defined 
microorganisms in sufficient numbers, which alter the microflora (by implantation 
or colonisation) in a compartment of the host and by that exert beneficial health 
effects in this host” (Schrezenmeir J, 2001). In October 2001, the most appropriate 
and widely used definition was finally developed by the World Health 
Organization (WHO) and the Food and Agriculture Organization (FAO) of the 
United Nations, as “Probiotics are live microorganisms, which, when administered 
in adequate amounts, confer a health benefit on the host". This definition has the 
following characteristics (Sanders ME, 2003):  
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1. Probiotics must be alive. Although it is recognised that dead cells may mediate 
physiological benefits, it was suggested that a different term refer to these 
agents, as consumer and scientific understanding is that probiotics are alive. 
2. Probiotics must deliver a measured physiological benefit, substantiated by 
studies conducted in the target host. 
3. Probiotics need not be restricted to food applications or oral delivery. 
Probiotics used as pharmaceuticals or as topical agents are not excluded from 
this definition. 
4. A definition of probiotics should not limit the mechanism of action. Therefore, 
survival of GI tract transit or impact on normal flora should not be required.  
For example, the delivery of lactase by, for example, Streptococcus 
thermophilus, to the small intestine was recognised as a probiotic activity. 
 
The use of probiotics in the dairy food processing, preservation and fermentation 
has been practiced for over a century. They are commercially available at the 
counter or chiller cabinet at supermarkets as bio-yogurts, probiotic drinks or food 
supplements. LAB such as lactobacilli and bifidobacteria are the most common 
probiotic strains used (O’May GA, 2005; Furrie E, 2005). Both organisms are 
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1.2.1 The genus Lactobacillus 
We encounter the members of Lactobacillus everyday. Lactobacilli are 
ubiquitously and heterogeneously found (Hammes WP, 1995). Non-pathogenic 
gram positive lactobacilli are generally regarded as safe (GRAS) and can be found 
in human GI tract. In healthy humans, lactobacilli are normally present in the oral 
cavity (103-104 cfu/g), the ileum (103-107 cfu/g) and colon (104-108 cfu/g), as well 
as in the vagina (Molin G, 1993; Ahrné S, 1998; Merk K, 2005). They produce 
lactic acid during the carbohydrate fermentation. It is easier to grow and store 
lactobacilli than bifidobacteria. They are well adapted to colonise the GI tract as 
they are acid- and bile salt-tolerant.   
 
1.2.2 Scientific classification of Lactobacillus  
The genus Lactobacillus was first described by Beijerinck in 1901. The scientific 








Species Lactobacillus plantarum, Lactobacillus rhamnosus etc. 
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1.2.3 Taxonomy of Lactobacillus genus  
The genus was subsequently divided into groups based on their phenotypic 
characteristics such as their optimal growth temperatures and hexose fermentation 
pathways (Orla-Jensen S, 1919), and later on obligate/facultative, 
homo/heterofermentation potential (Kandler O, 1986). Phenotype and 
phylogeny-based nomenclatures have been recently proposed. With the advances 
in the molecular genetic tools, the diversity of this genus has been extensively 
studied based on the 16S rRNA (Collins MD, 1991). New Lactobacillus species 
are being continually identified and described in the Approved List of Bacterial 
Names (Euzéby, www.bacterio.cict.fr). The change in the taxonomy of 
Lactobacillus is continuous and on-going: 44 species and 11 subspecies were 
described in 1986 (Kandler O, 1986), 88 species and 15 subspecies in 2003 
(Coeuret V, 2003) and 135 species and 27 subspecies in January 2007 
(www.bacterio.cict.fr). Some Lactobacillus species have been renamed or 
reclassified under new genera. Yet, some previously identified lactobacilli may 
still be subjected to change. 
 
1.2.4 Epidemiological studies on probiotics and allergy 
Based on the current epidemiological and observational data, different patterns of 
the gut microbiota composition have been reported in the intestines of non-allergic 
and allergic children. The first indirect evidence was shown in the Swedish and 
Estonian children (Sepp E, 1997). The incidence of allergic diseases was higher in 
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Sweden than in Estonia. Lactobacilli are reported to be found more commonly in 
Estonian infants than Swedish infants. Further studies have demonstrated that 
atopic infants are found to be less often colonised with enterococci and 
bifidobacteria but have higher counts of clostridia and staphylococcus during their 
early life (Björkstén B, 1999; Bottcher MF, 2000; Björkstén B, 2001). Similar 
phenomenon is observed among the Finnish children (Kalliomaki M, 2001) and 
Japanese children with atopic dermatitis (Watanabe S, 2003). Moreover, an 
association between the intestinal microbiota and IgE responses has been reported. 
Higher count of clostridia than that of bifidobacteria was found in 5-year-old 
Estonian atopic infants with specific IgE antibodies (Sepp E, 2005). Recent 
studies have also demonstrated that infants with higher counts of E. coli are more 
susceptible to the development of atopic symptoms (Penders J, 2006; Penders J, 
2007). On the other hand, Lactobacillus-containing product beneficially affects 
the homeostasis of the human faecal microbiota and may contribute to the 
health-promoting effects (Garrido D, 2005). These findings suggest the possible 
role of Lactobacillus in the primary prevention of allergic diseases in early life.  
 
1.2.5 Clinical studies of probiotics in the management of allergic disorders 
Lactobacilli have recently been advocated for the prevention and treatment of 
allergic diseases. Many clinical trials have been conducted in order to test the 
beneficial effects of probiotics in allergic diseases including atopic eczema, 
allergic rhinitis, allergic asthma and food allergy. Some clinical trials are still in 
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progress, whereas some studies have reported a failure of probiotics in the 
reduction of allergic symptoms or risk of allergic diseases (Helin T, 2002; 
Brouwer ML, 2006; Taylor AL, 2007). Prospective analysis of well-designed 
double-blinded placebo controlled clinical trials with recruitment of larger 
population is therefore necessary to examine the probiotic effects and assess its 
long-term outcomes. So far, none of these studies could draw any conclusion 
regarding the potential effect of Lactobacillus on the management of allergic 
diseases. Nevertheless, a number of clinical trials have been conducted showing 
the potential use of lactobacilli in the early prevention and treatment of allergic 
diseases.  
 
1.2.5.1 Probiotic prevention for atopic eczema  
To date, the use of probiotics in the prevention of atopic eczema is not widely 
studied. Kalliomaki M et al. first reported the reduced incidence of atopic eczema 
in Lactobacillus rhamnosus GG (LGG)-supplemented group (Kalliomaki M, 
2001). In this study, mothers received capsules containing LGG daily for two to 
four weeks before the expected delivery and to infants in the first six months of 
life. The frequency of atopic eczema in children at aged two in the probiotic group 
was half to that of the placebo group. The preventive effect of LGG on eczema 
extended to the age of four years, with no reduction in respiratory allergy and IgE 
titers (Kalliomaki M, 2003). Moreover, other studies have also shown that 
probiotics may reduce the incidence of IgE-associated eczema during early 
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infancy (Abrahamsson TR, 2007; Kukkonen K, 2007).  
 
1.2.5.2 Probiotic treatment for atopic eczema  
On the other hand, atopic eczema is the most widely studied disease by probiotic 
treatment. The down-regulation of allergic reactions and GI inflammation was 
first demonstrated in infants with atopic dermatitis and cow’s milk allergy 
(Majamaa H, 1997). The scoring atopic dermatitis (SCORAD) scores improved 
significantly in the LGG-supplemented group as compared to the placebo group. 
The second randomised controlled trials provided another clinical demonstration 
of specific probiotics modifying the changes related to allergic inflammation 
(Isolauri E, 2000). Two months after the weaning to extensively hydrolysed whey 
formula (eHF), a significant improvement in the SCORAD score was observed in 
the atopic patients treated with LGG or Bifidobacterium lactis. The probiotic 
effect was extended at the sixth month of the follow-up study.  
 
Moreover, the efficacy of oral supplementation of viable and non-viable LGG was 
assessed in the infants with atopic dermatitis and allergy to cow’s milk 
(Kirjavainen PV, 2003). A greater improvement in the SCORAD score was 
obtained in the viable LGG-supplemented group. As the treatment with non-viable 
LGG was associated with adverse GI symptoms and diarrhoea, this study was 
terminated early. The premature termination of this study has suggested that 
supplementation of infant formulas with viable but not heat-inactivated LGG is a 
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potential approach for the management of atopic eczema and cow’s milk allergy.  
 
In addition, older children with more severe atopic eczema were recruited in a 
randomised, double-blinded, placebo-controlled, crossover trial (Rosenfeldt V, 
2003). The mean SCORAD scores were improved in patients receiving the 
combined probiotic treatment of Lactobacillus rhamnosus 19070-2 and 
Lactobacillus reuteri DSM 122460 for six weeks.  
 
So far, the largest randomised, double-blinded, placebo-controlled study was 
conducted using 230 infants with moderate to severe eczema (Viljanen M, 2005). 
Disappointingly, no differences were found in the SCORAD scores between the 
probiotic group and placebo group. However, in a subgroup analysis, the LGG 
group showed a greater reduction in the SCORAD scores compared to the placebo 
group in IgE-sensitised infants. 
 
1.2.5.3 Probiotic treatment for allergic rhinitis and asthma 
In 1997, a study was performed to test the probiotic effect of fifteen adolescents 
and adults with allergic asthma (Wheeler JG, 1997). No significant difference was 
noted in the clinical parameters of asthmatic patients. Another clinical study in the 
treatment of allergic rhinitis was conducted in 33 adults and adolescents allergic to 
birch pollen (Helin T, 2002). The treatment commenced 2.5 months before and 
finished two months after the birch pollen season. However, the treatment did not 
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alleviate any of the allergic symptoms or use of medication in patients. On the 
other hand, Lactobacillus paracasei have been demonstrated to be effective in 
improving the overall quality of life for HDM-induced perennial allergic rhinitis 
patients (Wang MF, 2004; Peng GC, 2005). Thus, there is so far no strong 




1.3 Oral delivery of vaccines 
To date, there has been much attention in the development of an oral delivery 
vaccine. It offers a number of advantages over the parenteral vaccination. It causes 
no pain and less discomfort especially when repeated or routine administration is 
needed. It eliminates the possibility of cross-contamination and infections caused 
by injection. It does not require trained personnel and the oral vaccination is 
therefore relatively inexpensive. It is by far the easiest and most convenient means 
among the different routes of mucosal immunisation. Therefore, oral vaccination 
represents a better choice of administration as compared to the parenteral 
vaccination. 
 
Antigen degradation in the GI tract is a major hurdle in the oral delivery of 
antigen. As a result, the oral administration of antigen is always ineffective due to 
the antigen degradation in the GI tract prior to the priming and induction of an 
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immune response (Lee VHL, 1991). Several delivery systems have been devised 
to circumvent such obstacles. In general, there are two common ways to achieve 
the efficiency of oral delivery of antigens. A variety of synthetic delivery systems 
including nanoparticles, liposomes, and chitosan are currently being investigated. 
The use of viral or bacterial vectors represents another approach to antigen 
delivery via oral administration. The commonly studied viral or bacterial vectors 
are LAB and pathogenic microorganisms such as E. coli, Salmonella typhimurium, 
Listeria monocytogenes, Vibrio cholera, Mycobacterium bovis BCG. 
 
1.3.1 Unique features of lactobacilli as antigen-based oral delivery vehicles 
Over the past decade, there has been a growing interest in the use of lactobacilli as 
safe oral delivery vehicles. Some of the unique factors attributed to the selection 
of lactobacilli functioning as oral delivery vehicles are summarised as below: 
1. They are GRAS for human oral consumption and exert health-promoting 
effects. 
2. They can survive passage through human GI tract and possess adherence and 
colonisation capacities along human GI tract. 
3. They can be cultured easily and manipulated genetically, thus they can be 
engineered to express targeting antigen and possess intrinsic adjuvant 
properties to elicit antigen-specific immune responses. 
 
Lactobacilli with GRAS status are widely used in the food industries. As 
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compared to those pathogenic bacteria, lactobacilli can be administered live and 
have been consumed in large amounts by humans without causing any known 
detrimental health problems over centuries. Therefore, the use of live lactobacilli 
as oral delivery vehicles may eliminate issues that could be associated with 
attenuated pathogenic bacteria. In addition, acid- and bile salt-resistant lactobacilli 
can survive passage through human GI tract. They have overcome the major 
hurdle in the oral delivery of antigens. The adherence and colonisation capacities 
are also particularly attractive features of lactobacilli but not lactococci. Adhesion 
to the GI tract is a key factor affecting the capacity of lactobacilli to persist within 
the GI tract and to act as an adjuvant for the enhancement of specific immune 
response to orally administered antigen (Fang H, 2000; Plant LJ, 2002). As a 
result, lactobacilli are capable of eliciting local and systemic immune responses, 
thereby exerting their health promoting effects in human. As compared to 
bifidobacteria, lactobacilli are easier to be cultured and manipulated. In addition, a 
number of expression vectors were designed and constructed for the use in 
lactobacilli. The advances in the molecular tools for genetic manipulation have 
allowed genetically engineered Lactobacillus strains to function as live antigen 
delivery vehicles for targeting antigens to mucosa tissues (Pouwels PH, 1996; 
Pouwels PH, 1998; Pouwels PH, 2001), thereby effectively inducing 
antigen-specific protective immune responses (Kruger C, 2002; Pant N, 2006). 
Taken altogether, these attractive features make lactobacilli better choices for the 
development of safe and efficacious antigen-based oral delivery vaccines.   
   25
1.3.2 Mechanisms of lactobacilli as immunomodulator 
Mucosal surfaces represent a very large proportion of the surface area of the 
human body. The mucosa of the small intestine alone is estimated to be 300 m2 in 
humans (Moog F, 1981). Dendritic cells (DCs) are particularly abundant at 
mucosal sites and are recruited during infections to the site of mucosal 
inflammation. DCs are professional antigen presenting cells (APCs) which play a 
key role in the antigen sampling, early bacterial recognition, regulation of T cell 
immune responses as well as the induction of immunological tolerance 
(Banchereau J, 1998; Kaliński P, 1999; Kronin V, 2000; Banchereau J, 2000; 
Kapsenberg ML, 2003; Kelsall BL, 2004; Iwasaki A, 2007; Coombes JL, 2008).  
 
The induction of T cell responses requires three signals from DCs. Upon the 
exposure to antigen or microbial stimulation, the MHC class II and co-stimulatory 
molecules are upregulated on DC surface. DCs migrate to the draining lymph 
nodes. Followed by DC maturation, DCs present processed antigen to naïve T 
cells, thereby priming and inducing adaptive immune responses. The formation of 
MHC-Ag complexes is the first signal that determines the antigen specificity of 
the response. The second signal is provided by the co-stimulatory molecules 
expressed on DCs during the DC maturation. In the absence of the co-stimulatory 
molecules, Th cells become anergic which might lead to tolerance. In addition, 
mature DCs secrete multiple cytokines for the subsequent T cell differentiation 
and polarisation.  
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DC-derived cytokines play the most important role in the T cell polarisation 
towards Th1 or Th2 or T regulatory (Treg) cell development (Mazzoni A, 2004). 
Interleukin-12 (IL-12) family members such as IL-12, IL-23 and IL-27 have been 
reported as strong Th1-skewing cytokines which mediate the production of IFN-γ 
by Th1 cells (Hsieh CS, 1993; Heufler C, 1996; Mosmann TR, 1996; O'Garra A, 
1998; Trinchieri G, 2003). DCs produce IL-12 upon interaction between CD40 on 
the APC and the rapidly induced CD40 ligand (CD40L, CD154) on the activated 
Th cell (Koch F, 1996; Cella M, 1996; Hilkens CM, 1997). Conversely, exposure 
of naïve T cells to IL-4, IL-5, IL-10 and IL-6 results in Th2 cell development. 
Notably, IL-10 is a pleiotropic cytokine that modulates the function of several 
adaptive immunity-related cells by promoting either Th2 immune response or the 
generation of Treg cells with an immunosuppressive function (Mocellin S, 2004). 
IL-10 and transforming growth factor-β (TGF-β) are well documented as 
regulatory T cell-polarising factors (Groux H, 1996; Zeller JC, 1999; Akbari O, 
2001). IL-6 is mainly produced by APCs. IL-6 promotes terminal differentiation 
of B cells into plasma cells, induces Th2 cell polarisation (Rincón M, 1997), and 
enhances the intestinal IgA response (McGhee JR, 1991; Ramsay AJ, 1994; 
Braciak TA, 2000). 
 
Recent findings have suggested that Lactobacillus strains, with their own intrinsic 
adjuvant properties, could differentially modulate the surface marker expression 
and cytokine production by DCs, with the possibility to favour Th1, Th2 or Th3 
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immune responses (Christensen HR, 2002; Drakes M, 2004; Hart AL, 2004; 
Mohamadzadeh M, 2005; Niers LE, 2007). In addition, Smith et al. has 
demonstrated that Lactobacillus strains, which bind the C-type lectin DC-specific 
intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN), can actively 
prime DCs to the development of IL-10-producing Treg cells (Smits HH, 2005). 
This suggests that Lactobacillus strains, which are potent IL-12 or IL-10 inducers, 
can differentially modulate DCs, thereby promoting Th1 or Treg cell development 
to antagonise Th2 immune response. 
 
1.3.3 Strain selection 
The proper selection of Lactobacillus strains is crucial for the development of an 
oral vaccine for the management of allergic diseases. Based on the effects of their 
intrinsic adjuvanicity, some Lactobacillus strains could potentially suppress the 
Th2-mediated allergic diseases by the immune deviation to Th1-type immune 
response (Murosaki S, 1998; Repa A, 2003; Hisbergues M, 2007) or Treg 
activation. 
 
1.3.3.1 Lactobacillus plantarum 
Lactobacillus plantarum is a potent inducer of IL-12, directing the Th1 cell 
development (Hessle C, 1999; Repa A, 2003). Lactobacillus plantarum is more 
immunogenic than Lactococcus lactis (Grangette C, 2004; Cortes-Perez NG, 
2007). Lactobacillus plantarum is shown to induce IL-10 production by DCs and 
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CD4+ T cells, thereby enhancing the efficacy of SLIT (Van Overtvelt L, 2008). 
Furthermore, Lactobacillus plantarum has been used in the studies of birch pollen 
(Repa A, 2003; Daniel C, 2006) and dust mite allergy (Pochard P, 2005; 
Hisbergues M, 2007). Studies have shown that Lactobacillus plantarum is capable 
of inducing Th1- or Treg-type immune responses (Repa A, 2003) and suppressing 
the airway inflammation in mice (Daniel C, 2006). The co-administration of 
Lactobacillus plantarum and mite allergen is capable of inducing the production 
of IL-10 and IL-12 by monocyte-derived DCs from allergic patients (Pochard P, 
2005). This suggests that Lactobacillus plantarum might have the capacity to 
switch the established Th2 response in mite allergic patients towards Th1 response. 
Besides, the co-administration of Lactobacillus plantarum and Der p 1 has been 
shown to prevent the development of the allergic response in mice (Hisbergues M, 
2007). More recently, recombinant Lactobacillus plantarum expressing Der p 1 
represents a promising prophylactic vaccine against mite allergy. It has been 
shown to induce antigen-specific immune responses and reduce allergic airway 
eosinophilia upon the aerosol challenge of allergen (Rigaux P, 2009).  
 
1.3.3.2 Lactobacillus rhamnosus GG 
Lactobacillus rhamnosus GG (LGG) is one of the best-studied probiotic bacteria. 
Clinical trials have shown that LGG effectively prevents early atopic disease in 
children at high risk (Kalliomaki M, 2001; Kalliomaki M, 2003). Treatment with 
LGG has led to an increase in the production of IFN-gamma in infants with cow's 
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milk allergy (Pohjavuori E, 2004) and the alleviation of atopic eczema/dermatitis 
syndrome in IgE-sensitised food allergic infants (Viljanen M, 2005). In addition, 
Feleszko W et al. has reported that the administration of LGG suppresses the 
asthmatic phenotype such as airway reactivity, antigen-specific immunoglobulin E 
production and pulmonary eosinophilia in newborn mice. An induction of T 
regulatory cells associated with increased TGF-β production is observed (Feleszko 
W, 2007). Several reports suggest that the bacterial cell wall components and 
soluble factors of LGG might contribute to its immunomodulatory ability 
(Miettinen M, 2000; Matsuguchi T, 2003; Pena JA, 2003). More recently, 
LGG-derived immunostimulatory oligodeoxynucleotide (ISS-ODN) ID35 is 
shown to exert anti-allergic effect by activating DC, eliciting effective Th1 
responses and suppress antigen-specific IgE production in vivo (Iliev ID, 2008). 
The effect of ID35 on switching the Th bias to a non-allergic Th1 response and on 
the suppression of ovalbumin (OVA)-specific IgE production was comparable 
with the effect induced by murine prototype CpG 1826.  
 
Taken together, Lactobacillus plantarum and LGG might represent potential 





   30
1.4 The rationale of the study 
Recent studies have demonstrated that Blo t 5 is the major indoor HDM allergen 
in the tropical and subtropical countries such as Singapore, Malaysia, Hong Kong, 
Thailand, Taiwan and many more. In view of the clinical importance of Blo t 5 in 
these geographical regions, its role as a part of armamentarium of therapeutic 
agents used for the allergen-specific immunotherapy for allergic diseases should 
not be neglected.  
 
Defects in the development of regulatory T cells have been implicated in the 
development of allergic diseases. Strategies that restore immune regulation may 
potentially be exploited as clinical interventions. Probiotics is one such modality 
and has been used in clinical trials for the prevention and treatment of allergic 
diseases and inflammatory bowel disease. Hygiene hypothesis has also suggested 
a possible role of Lactobacillus in the primary prevention of allergic diseases early 
in life. Some epidemiological studies have revealed that the composition of the 
gut microbiota differs in healthy and allergic infants. Moreover, several clinical 
studies have showed promising data on lactobacilli effects in atopic diseases. 
Some preclinical studies using allergen-expressing recombinant lactobacilli have 
also demonstrated that it could be a promising strategy to attenuate allergic airway 
inflammation. Taken together, recombinant lactobacilli are potential candidates for 
the development of antigen-based oral vaccines in the primary prevention and 
management of allergic diseases.  
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Experimental data have indicated that Lactobacillus plantarum is a potent IL-12 
inducer, whereas LGG is a potent IL-10 inducer. Therefore, Lactobacillus 
plantarum NC8 and LGG are chosen and genetically engineered to express Blo t 5 
in this project. The hypothesis of this study are that (1) recombinant Lactobacillus 
plantarum NC8 and recombinant LGG expressing Blo t 5 could induce Blo t 
5-specific immune responses which can antagonise the Blo t 5-mediated Th2 
immune response; (2) Lactobacillus plantarum NC8 and LGG exhibit differential 
intrinsic adjuvanicity that may lead to differential immunomodulatory effects on 
differentiation of antigen-specific T subsets.  
 
To date, LGG has not been explored and studied as a host strain expressing 
allergen. This study is the first to explore and compare the immunomodulatory 
and protective effects of recombinant Lactobacillus plantarum NC8 with 
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1.5 The specific aim and experimental strategies of the study  
The specific aim of this study is to evaluate the protective and immunomodulatory 
effects of recombinant Lactobacillus strains expressing Blo t 5 in prevention and 
treatment of allergic asthma in a mouse allergy model.    
 
The experimental strategies used in the study are as followed: 
1. Construction of plasmid pSIP412 containing the cDNA encoding for the  
major mite allergen Blo t 5 (designated as pSIP412-Bt5) 
2. Generation of recombinant Lactobacillus plantarum NC8 and recombinant 
LGG expressing Blo t 5 (designated as rLp and rLGG, respectively) 
3. Evaluation of the expression levels of Blo t 5 in recombinant Lactobacillus 
plantarum NC8 and recombinant LGG 
4. Evaluation of the effects of recombinant Lactobacillus plantarum NC8 and 
recombinant LGG on the phenotype and cytokine production profiles of 
bone marrow-derived dendritic cells (BMDCs) and Flt3-derived DCs  
5. In vivo evaluation of the immunogenicity of recombinant Lactobacillus 
plantarum NC8 and recombinant LGG in naïve mice  
6. In vivo evaluation of the anti-allergic immunomodulatory effects of 
recombinant Lactobacillus plantarum NC8 and recombinant LGG in 
mouse allergy model. 
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Chapter 2 




2.1.1 Yeast and bacterial strains 
Pichia pastoris strain KM71 [Genotype: aox1::ARG4, arg4 Muts] was purchased 
from Invitrogen (Carlsbad, CA, USA) and used for the expression of recombinant 
Blo t 5.  
 
Lactococcus lactis subspecies cremoris MG1363 was used as intermediate host 
for plasmid propagation. Lactobacillus plantarum NC8 and Lactobacillus 
rhamnosus GG (ATCC 53103) were used as final hosts for protein expression. The 
characteristics of the bacterial strains used are listed in the Table 2.1. Lactococcus 
lactis subspecies cremoris MG1363 and Lactobacillus plantarum NC8 were 
generously provided by Dr. Lars Axelsson (Matforsk, Norwegian Food Research 






Table 2.1 The characteristics of plasmid and bacterial strains used in this study 
 





EmR, inducible PorfX,   
Lactococcus lactis pSH71 replicon, 
pepN reporter gene 
 
Sørvig E (1983) 
 
Vector map (Appendix 5),  
DNA sequence (Appendix 6) 
 
Lactococcus lactis  
subspecies cremoris MG1363 (Ll) 
 
Host strain, plasmid-free,  
prophage-cured derivative of 
Lactococcus Lactis NCDO 712 
Gasson MJ (1983)  
Lactobacillus plantarum NC8 (Lp) Host strain, silage isolate, plasmid-free 
 
Aukrust T  (1992) 
 
 
Lactobacillus rhamnosus GG (LGG) 
(ATCC 53103)  Host strain, human isolate, plasmid-free 
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2.1.2 Yeast and bacterial culture media 
Yeast nitrogen base (YNB), Bacto-yeast extract, Bacto-peptone, Bacto-tryptone, 
Bacto-agar, gelatin and MRS broth were purchased from Difco Laboratories 
(Sparks, MD, USA). M17 broth and M17 agar were purchased from Oxoid 
(Basingstoke, Hampshire, England). Sodium chloride, potassium phosphate 
monobasic, potassium phosphate dibasic, magnesium chloride, calcium chloride 
and methanol and were purchased from Merck (Whitehouse station, NJ, USA). 
Glycerol was purchased from Univar (Kirkland, WA, USA). Glycine, glucose, 
histidine, biotin and erythromycin were purchased from Sigma (St. Louis, MO, 
USA). Sucrose was purchased from 1st Base Pte Ltd (Singapore).  
 
2.1.3 Reagents for protein purification, identification and analysis 
Butyl Sepharose 4 Fast Flow and Q-Sepharose Fast Flow were purchased from 
Pharmacia (Uppsala, Sweden). Blo t 5-specific monoclonal antibody (mAb) 4A7 
was generated in our laboratory as previously described (Yi FC, 2005). 
Biotinylated anti-mouse immunoglobulins and ExtrAvidin® Peroxidase conjugate 
were purchased from Sigma (St. Louis, MO, USA). HybondTM-C Extra 
nitrocellulose membrane was purchased from Amersham Biosciences (Amersham 
Place, Little Chalfont, Bucks, UK). Bio-safe Coomassie stain was purchased from 
Bio-Rad (Hercules, CA, USA). SuperSignal West Pico Chemiluminescent 
Substrate and Kodak BioMax film were purchased from Pierce (Rockford, IL, 
USA) and Eastman Kodak Company (Rochester, NY, USA), respectively.  
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2.1.4 Plasmid and reagents for molecular cloning 
pSIP412 expression vector (Figure 2.1, Appendix 5) was a kind gift from Dr. Lars 
Axelsson (Matforsk, Norwegian Food Research Institute, Osloveien, Norway). 
Taq DNA polymerase was purchased from Roche (Indianapolis, IN, USA). 
Klenow polymerase, Xho I, Nco I, T4 DNA ligase and Wizard® Plus SV miniprep 
DNA purification system were purchased from Promega (Madison, WI, USA). 
GFX PCR DNA and gel band purification kit was purchased from GE Healthcare 
(Little Chalfont, Buckinghamshire, UK). BigDye® Terminator v3.1 Cycle 
Sequencing R-100 Kit was purchased from Applied Biosystems (Foster City, CA, 
USA). Lysozyme from chicken egg white was purchased from Sigma (St. Louis, 
MO, USA).  
 
2.1.5 Mice 
Female C57BL/6J mice, 4-6 weeks of age, were purchased from Centre for 
Animal Resources (CARE) at Lim Chu Kang and housed under conventional 
condition (temperature 22ºC and relative humidity 65%) in the National 
University of Singapore (NUS) Animal Holding Unit (AHU). Food and water 
were available ad libitum. All experiments were performed according to the 






















Figure 2.1 Schematic diagram of the pSIP412 expression vector. 
Horizontally hatched regions: reporter gene (pepN); Dotted regions: inducible 
promoter (PorfX); Light-grey regions: replication determinants (SH71rep); 
Dark-grey regions: erythromycin resistance marker (ermB); White regions: 
inducible sppIP promoter (PsppIP); Vertically hatched regions: histidine protein 
kinase and response regulator genes; Lollypop structures, transcriptional 
terminator; Black boxes: multiple cloning sites (MCS; SphI, XbaI, XhoI, EcoR1, 




 (8,405 bp) 
SH71 rep 
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2.1.6 Inducing peptide for protein induction 
Sakacin P inducing peptide (SppIP, MAGNSSNFIHKIKQIFTHR, 
C99H157N31O26S1) was synthesized by 1st Base Pte Ltd (Singapore). The purity is > 
90% by HPLC.  
 
2.1.7 Reagents for mice immunization 
Amphojel® Aluminum hydroxide (alum) was purchased from Whitehall 
Laboratories Pty Ltd (Australia). 
 
2.1.8 Reagents for cell culture 
Hanks’ balanced salt solution (HBSS) without calcium and magnesium was 
purchased from Sigma (St. Loius, MO, USA). RPMI 1640 medium, penicillin, 
streptomycin, L-glutamine and sodium pyruvate were purchased from Hyclone 
(Logan, Utah, USA). Fetal bovine serum was purchased from PAA Laboratories 
GmbH (Haidmannweg, Pasching, Austria). 2-Mercaptoethanol was purchased 
from Gibco (Grand Island, NY, USA). Ficoll-Paque plus was purchased from 
Amersham Biosciences Corp (Piscataway, NJ). OptiPrepTM density gradient media 
was purchased from Axis Shield Poc AS (Oslo, Norway). Mitomycin-C was 
purchased from Roche Diagnostic GmbH (Mannheim, Germany). 
 
Complete RPMI 1640 medium was supplemented with 10% (vol/vol) 
heat-inactivated fetal bovine serum, 100 U/ml of penicillin, 100 μg/ml 
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Streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate and 5.5 x 10-2 mM 
2-Mercaptoethanol. Complete RPMI 1640 medium was used for all cell culture 
experiments.  
 
2.1.9 Antibodies and recombinant cytokines  
Purified mouse antibodies IgE and IgG1 as well as recombinant mouse cytokines 
IL-2, IL-4, IL-5, IL-6 and TGF-β were purchased from BD Pharmingen (San 
Diego, CA, USA). Recombinant mouse cytokines IL-10, IL-12, IL-13, IFN-γ and 
TNF-α were purchased from R&D systems (Minneapolis, USA). Recombinant 
mouse GM-CSF and mouse Flt3L were purchased from PeproTec Inc. (Rocky 
Hill, NJ).  
 
PE-conjugated anti-mouse CD40 (clone 1C10) was purchased from eBioscience 
(San Diego, CA, USA). APC-conjugated anti-mouse CD11c (clone HL3), 
FITC-conjugated anti-mouse I-Ab (clone AF6-120.1), FITC-conjugated 
anti-mouse CD80 (clone 16-10A1), PE-conjugated anti-mouse CD86 (clone GL1), 
purified mAbs against mouse Ig κ light chain (clone 187.1), IL-4 (clone 
BVD4-1D11), IL-5 (clone TRFK5), IL-6 (clone MP5-20F3), IFN-γ (clone 
R4-6A2), TGF-β (A75-2.1), as well as biotin-conjugated mAbs against mouse 
IL-4 (clone BVD6-24G2), IL-5 (clone TRFK4), IL-6 (clone MP5-32C11), IFN-γ 
(clone XMG1.2), TGF-β(clone A75-3.1), were purchased from BD Pharmingen 
(San Diego, USA) 
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Purified mAbs against mouse IL-10 (clone JES052A5), IL-12p70 (clone 48110), 
IL-13 (clone 38213), polyclonal Abs against mouse TNF-α as well as 
biotin-conjugated polyclonal Abs against mouse IL-10, IL-12, IL-13 and TNF-α 
were purchased from R&D systems (Minneapolis, USA). 
  
Biotin conjugated anti-mouse IgE (clone LO-ME-3) and IgG1 (clone LO-MGI-2) 
were purchased from Serotec (Oxford, England). ExtraAvidine Alkaline 
Phosphatase conjugate, Sigma Fast p-Nitrophenyl phosphatase substrate (pNPP), 
2,2’-Azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) tablets (ABTS), 
phosphate-citrate buffer with urea hydrogen peroxide tablet and bovine serum 
albumin (BSA) were purchased from Sigma (St. Louis, MO, USA). Mouse IgG2c 
ELISA Quantitation Kit was purchased from Bethyl Laboratories Inc. 




2.2.1 Purification of recombinant Blo t 5 
Recombinant Blo t 5 (rBlo t 5) was produced from the Pichia pastoris yeast 
expression system (Goh LT, 2001). Briefly, the Pichia pastoris KM71 
transformants carrying Blo t 5 cDNA were grown in 6 L of buffered 
glycerol-complex medium (1% yeast extract, 2% peptone, 1.34% yeast nitrogen 
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base with ammonium sulfate, 1% glycerol, 0.4 mg/L biotin, and 0.1 mol/L 
potassium phosphate, pH 6.0) until the OD600 = 6. Cells were harvested by 
centrifugation at 1000g and gently suspended in 600 mL of buffered 
methanol-complex medium containing 0.5% methanol. The cells were cultured for 
another 2 days for Blo t 5 induction. Methanol was replenished to 0.5% final 
concentration every 24 hours. The yeast media containing rBlo t 5 was processed 
by conventional fast performance liquid chromatography (Goh LT, 2001). Purified 
rBlo t 5 was analyzed by SDS-PAGE and confirmed by western blot. The 
concentration of rBlo t 5 was determined using the UV absorbance spectroscopy 
method.  
 
2.2.2 Gel electrophoresis  
2x SDS sample buffer (0.1 M Tris-HCl (pH 6.8), 4% SDS, 12% 
2-Mercaptoethanol, 20% glycerol, 10 mM dithiothreitol (DTT) and a small 
amount of bromophenol blue) was added at equal volume to each protein sample. 
The samples were boiled for 5 mins prior to gel loading. Proteins were 
subsequently separated on 7.5% SDS-PAGE. Protein bands were identified by 
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2.2.3 Western blotting 
Proteins were separated on 7.5% SDS-PAGE and electroblotted onto HybondTM-C 
extra nitrocellulose membrane (Amersham Biosciences, Amersham Place, Little 
Chalfont, Bucks, UK). After blocking with 5% milk in tris buffered saline (TBS) 
containing 0.05% Tween-20 (TBS-T), the blot was washed 3 times with TBS-T 
and incubated with 2 ml of diluted mAb 4A7 at 4°C overnight. The blot was 
washed 5 times with TBS-T and incubated with biotinylated anti-mouse 
immunoglobulins at a dilution of 1:5000 (Sigma, St. Louis, MO, USA). The blot 
was washed 5 times with TBS-T and incubated with ExtrAvidin peroxidase 
conjugate at a dilution of 1:10000 (Sigma, St. Louis, MO, USA) at room 
temperature for 1 hour. The blot was washed 6 times with TBS-T and signals were 
developed with SuperSignal West Pico chemilumisnescent substrate (Pierce, 
Rockford, IL, USA) on BioMax film (Eastman Kodak Company, Rochester, NY, 
USA). 
 
2.2.4 Bacterial growth conditions 
Lactococcus lactis subspecies cremoris MG1363 was grown in GM17 medium. 
Lactobacillus plantarum NC8 and LGG were grown in MRS medium (Difco, 
Becton Dickinson, USA). Lactococcus lactis and Lactobacillus strains were 
grown in unshaken cultures at 30ºC. Erythromycin at a final concentration of 5 
μg/ml was added as a selection antibiotic for recombinant Lactococcus lactis and 
recombinant lactobacilli. The detailed recipe of the culture media used for 
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Lactococcus lactis and Lactobacillus strains were listed in Appendix 3 and 
Appendix 4. 
 
2.2.5 The construction of pSIP412-Bt5 expression vector 
The construction of pSIP412-Bt5 expression vector was schematically shown in 
Figure 2.2. Briefly, the pSIP412 vector was digested with Nco I (Promega, 
Madison, WI, USA), treated with Klenow polymerase (Promega, Madison, WI, 
USA) to fill in the protruding end and further digested with XhoI (Promega, 
Madison, WI, USA). The coding sequence of mature Blo t 5 protein (see 
Appendix 1) was amplified from a recombinant plasmid pGEX-4T1-Bt5 (Yi FC, 
2004) by polymerase chain reaction (PCR) using Taq DNA polymerase (Roche, 
Indianapolis, IN, USA). The sequences of Blo t 5-specific sense and antisense 
primers (1st Base Pte Ltd, Singapore) used were 
5’-CAAGAGCACAAGCCAAAGAAGG-3’ and 
5’-CGCTCGAGTTATTGGGTTTGAATATCCTT-3’, respectively. The antisense 
primer was designed to contain an Xho I restriction site (underlined). The 
conditions of the PCR were: 94°C for 5 min; 30 cycles of 94°C for 30 sec, 58°C 
for 30 sec and 72°C for 30 sec; 72°C for 10 min. PCR product was subsequently 
digested with Xho I. The resulting plasmid and the digested PCR fragment were 
ligated by using T4 DNA ligase (Promega, Madison, WI, USA). The ligation 
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Figure 2.2 The schematic representation of the construction of pSIP412-Bt5 
expression vector. The aminopeptidase N (pepN) reporter gene of the pSIP412 
plasmid was removed by double digestion with Ncol and Xhol. The sequence 
encoding for the full length Blo t 5 was amplified from pGEX-4T1-Bt5, digested with 
XhoI and cloned into the blunt end at Klenow polymerase-treated NcoI site and 
cohesive end at XhoI site of pSIP412 to generate pSIP412-Bt5. 
 
 
Blo t  5 cDNA 
XhoI
5’ -      - 3’ Blo t 5 cDNA Digested pSIP412  5’ -                                                          - 3’
1. NcoI digestion 
2. Klenow polymerase 


















Blo t 5 
(351 bp) 
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The stepwise transformation procedures were summarized in Figure 2.3. Briefly, 
the ligation mixture was electrotransformed into Lactococcus lactis subspecies 
cremoris MG1363 as an intermediate host for plasmid propagation (section 2.2.6). 
pSIP412-Bt5 was extracted and nucleotide sequences were confirmed by DNA 
sequencing (section 2.2.7). Recombinant plasmid pSIP412-Bt5 was finally 
electrotransformed into Lactobacillus plantarum NC8 and LGG as final hosts for 
Blo t 5 expression (section 2.2.8). 
 
2.2.6 Electrotransformation of Lactococcus lactis  
Lactococcus lactis subspecies cremoris MG1363 was used as an intermediate host 
for plasmid propagation. The electroporation was conducted by using a Bio-Rad 
Gene Pulser Xell apparatus (Bio-Rad, Hercules, CA, USA) as described (Holo H, 
1989). Briefly, the mixture of Lactococcus lactis competent cells and ligation 
mixture was transferred into an ice-cold 2 mm disposable electroporation cuvette 
(Bio-Rad, Hercules, CA, USA). A single pulse was delivered with the following 
settings: voltage, 2.0 kV; capacitance, 25 μF; resistance, 200 Ω. These settings 
gave a time constant of 4-5 ms. Immediately following the pulse, bacteria were 
resuspended in SGM17MC and incubated at 30ºC for 2 hours. Transformants were 
selected by plating the bacteria on SR agar plate containing 5 μg/ml of 
erythromycin. Transformants were visible after incubation at 30ºC for 2 to 3 days. 
The detailed recipe of the culture media used for Lactococcus lactis was listed in 
Appendix 3.  





































Figure 2.3 The schematic diagram showing the strategy for the generation 
of recombinant lactobacilli carrying pSIP412-Bt5. The ligation mixture was 
electrotransformed into the intermediate host Lactococcus lactis subspecies 
cremoris MG1363 for plasmid propagation. Small scale plasmid extraction was 
performed by miniprep and nucleotide sequences were confirmed by DNA 
sequencing. The pSIP412-Bt5 was finally electrotransformed into Lactobacillus 






Lactococcus lactis cremoris MG1363 
miniprep 
Final hosts: 
1. Lactobacillus plantarum NC8  
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2.2.7 Plasmid extraction and DNA sequencing 
Small-scale plasmid extraction was performed by using Wizard® Plus SV 
miniprep DNA purification system (Promega, Madison, WI, USA) with little 
modification as described (O'sullivan DJ, 1993). Briefly, 3 ml overnight culture of 
recombinant Lactococcus lactis was centrifuged at 3,000 rpm for 10 mins. The 
bacterial pellet was resuspended in 250 μl of resuspension buffer containing 30 
mg/ml of lysozyme and incubated at 37ºC for 20 mins. The subsequent steps 
followed the manufacturer’s instructions. DNA sequencing was done by using the 
BigDye® Terminator v3.1 Cycle Sequencing R-100 Kit (Applied Biosystems, 
Foster City, CA, USA), according to the manufacturer’s recommendation. 
 
2.2.8 Electrotransformation of Lactobacillus strains 
Recombinant plasmid pSIP412-Bt5 was finally electroporated into Lactobacillus 
plantarum NC8 and LGG as described (Aukrust TW, 1995). Briefly, a single pulse 
of voltage, 1.5 kV; capacitance, 25 μF; resistance, 800 Ω was delivered. These 
settings gave a time constant of approximately 10 ms. Immediately following the 
pulse, bacteria were resuspended in MRSSM and further incubated at 30ºC for 2 
hours. Transformants were selected by plating the bacteria on MRS agar plate 
containing 5 μg/ml of erythromycin. Transformants were visible after incubation 
at 30ºC for 2 to 3 days. The detailed recipe of culture media used for 
Lactobacillus strains was listed in Appendix 4. 
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2.2.9 The induction and quantification of Blo t 5 expression in 
recombinant lactobacilli 
Recombinant Lactobacillus plantarum NC8 and recombinant LGG were grown in 
MRS broth containing 5 μg/ml of erythromycin at 30ºC. When the OD600 reached 
0.3, the Blo t 5 expression was induced by adding Sakacin P inducing peptide 
(SppIP) into the bacteria culture to a final concentration of 50 ng/ml (Sørvig E , 
2005). The bacteria were cultured for additional 4 hours. A billion bacterial cells 
were harvested, washed with phosphate buffered saline (PBS) and finally 
resuspended in 200 μl of PBS. The bacterial counts were determined by OD600 
where there is an estimation of 5 x 108 cfu/ml of bacteria at OD600 = 1. Bacterial 
cell suspensions were transferred into 1.5 ml tubes containing 0.1 g of 0.1 mm 
silica beads (Biospec Inc, Bartlesville, OK, USA). Cell lysates were prepared by 
vigorous shaking in a Bead-Beater (Biospec Inc, Bartlesville, OK, USA) with 
maximal speed for 90 secs. Twenty microliters of samples containing known 
colony forming units (cfu) of recombinant lactobacilli were separated on 7.5% 
SDS-PAGE and subjected to western blotting probed with ascites fluid at a 
dilution of 1:3. Ascites fluid was obtained from mice injected with hydridoma 
clones which produce mAb 4A7 as described (Yi FC, 2005). The gel image was 
captured using a densitometer LAS-3000 (Fujifilm, Stanford, CA). Each band 
density was measured in arbitrary units (AU unit) by using Multi Gauge general 
purpose analysis software (version 3.0). Different amounts (20, 40 and 80 ng) of 
recombinant yeast Blo t 5 were included and used as standard references. A 
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conversion graph of Blo t 5 amount (ng; y-axis) against band density (AU; x-axis) 
was plotted in order to estimate the amount of Blo t 5 expressed by recombinant 
Lactobacillus plantarum NC8 and recombinant LGG. 
 
2.2.10 The Blo t 5 stability in recombinant LGG 
The Blo t 5 expression in recombinant LGG was induced as described in section 
2.2.9. Four hours after the induction of Sakacin P inducing peptide, 10 ml of 
bacterial cultures were harvested, washed with MRS broth and finally 
resuspended in 10 ml of MRS broth without Sakacin P inducing peptide. The 
bacteria were cultured for another 20 hours. 1 ml of bacterial culture was 
harvested at every hour up to 20 hours. Each sample containing one-tenth of 
bacterial cell lysates collected was separated on 7.5% SDS-PAGE and subjected to 
western blot probed with ascites fluid. 
 
2.2.11 Preparation of live and heat-killed lactobacilli 
Wildtype lactobacilli were grown in MRS broth whereas recombinant lactobacilli 
were grown in MRS broth containing 5 μg/ml erythromycin. When OD600 reached 
0.3, the Blo t 5 expression was induced in recombinant lactobacilli by the addition 
of Sakacin P inducing peptide. The cultures of recombinant lactobacilli were 
incubated for additional 4 hours. The bacterial suspensions of wildtype lactobacilli 
and SppIP-induced recombinant lactobacilli were centrifuged at 3,000 rpm for 10 
mins. For the preparation of live bacteria, lactobacilli were washed 2 times with 
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sterile PBS and finally resuspended in PBS to a final concentration of 5 x 1010 
cfu/ml. For the preparation of heat-killed bacteria, lactobacilli were resuspended 
in PBS to a final concentration of 2 x 109 cfu/ml. Heat-killed lactobacilli were 
prepared by heating the bacterial suspension in a 70ºC waterbath for 1 hour. The 
viability was determined by plating on MRS agar plates. No bacterial growth was 
detected after incubation at 37ºC for 72 hours. 
 
2.2.12 Bone marrow-derived dendritic cells and bacteria coculture 
Bone marrow cells were isolated and cultured as described with minor 
modifications (Lutz MB, 1999). Briefly, femora and tibiae of female 8-week-old 
C57BL/6 mice were removed and stripped of muscles and tendons (see Appendix 
6). Both ends were cut. The marrow was flushed with complete RPMI 1640 
medium using a 27-gauge needle. Cell suspension was centrifuged at 1300 rpm 
for 5 mins. Red blood cells were lysed by adding 1.5 ml of pre-warmed RBC lysis 
buffer (10 mM Tris, 0.83% NH4Cl, pH 8.3) for 90 secs. Cells were washed 3 times 
with HBSS and finally resuspended in complete RPMI 1640 medium. The cell 
number was determined by using a hemocytometer. 
 
Six million of cells were plated in Petri dish (92 mm x 17 mm; Nunc, Roskilde, 
Denmark) in 10 ml complete RPMI 1640 medium containing 40 ng/ml of 
GM-CSF (Peprotech, Rocky Hill, NJ). Cells were incubated at 37°C in a 5% CO2 
humidified incubator. On day 3, an additional 10 ml of freshly complete RPMI 
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medium containing 40 ng/ml of GM-CSF was added into each plate. On day 6, 
non-adherent cells were harvested by gentle pipetting. BMDCs were enriched by 
OptiPrepTM gradient centrifugation according to the manufacturer’s 
recommendation (Axis Shield PoC AS, Oslo, Norway). Cells were washed 3 times 
with HBSS and finally resuspended in complete RPMI medium. The cell number 
was determined by using a hemocytometer.  
 
A total of 1 x 106 BMDCs were plated in 1ml of complete RPMI medium in 
6-well plate. BMDCs were co-cultured with wildtype or recombinant lactobacilli 
at DCs to bacteria (DCs:bacteria) ratio of 1:10 or 1:100 in the presence of 20 
ng/ml of GM-CSF at 37°C in a 5% CO2 humidified incubator. After 20-24 hours 
of stimulation, culture supernatants were collected for cytokine measurement by 
ELISA (section 2.2.23). The pulsed BMDCs were harvested for surface marker 
staining (section 2.2.13) or co-cultured with Blo t 5-specific T cells (section 
2.2.14). 
 
2.2.13 Surface marker staining of pulsed BMDCs 
Pulsed BMDC were washed with PBS containing 1% BSA and subsequently 
labeled with fluorescence-conjugated mAbs at 4°C for 30 mins in 5 ml Falcon® 
polystyrene round-bottom tube (Becton Dickinson, JA, USA). Cells were washed 
2 times with PBS containing 1% BSA and fixed with 1% paraformaldehyde. Flow 
cytometer was performed by using FACSCalibur and the data were analyzed by 
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using the CellQuestTM software (Becton Dickinson, CA, USA). The following 
antibodies were used for surface marker staining: APC-conjugated anti-mouse 
CD11c, FITC-conjugated anti-mouse I-Ab, FITC-conjugated anti-mouse CD80, 
PE-conjugated anti-mouse CD86 and PE-conjugated anti-mouse CD40. 
 
2.2.14 Co-culture of lactobacilli-pulsed BMDCs and Blo t 5-specific T cells 
Pulsed BMDCs were co-cultured with 5 x 104 Blo t 5-specific T cells at a DC:T 
ratio of 0.2:1 or 1:1 in 96-well U-bottom microplate (Nunc, Roskilde, Denmark). 
Cultures were incubated at 37°C for 72 hours in a 5% CO2 humidified incubator. 
Culture supernatants were collected for T cell cytokine measurement by ELISA 
(section 2.2.23). For the T cell proliferation assay, 1 μCi of [3H]-thymidine 
(Radiochemical Centre, Amersham, Little Chalfont, UK) was added into each well 
at 20 hours before cell harvest. On day 3, cells were harvested onto a glass fiber 
filter (Skatron instruments AS, Lier, Norway). After adding the scintillation fluid 
(Amersham Biosciences Corp), radioactivity was measured by multi-purpose 
scintillation counter LS 6500 (Beckman, Fullerton, CA, USA).  
 
2.2.15 Flt3-derived dendritic cells 
Bone marrow cells were obtained as previously described in section 2.2.12. Bone 
marrow cells were resuspended at 2 x 106 cells/ml in complete RPMI 1640 
medium containing 200 ng/ml mouse Flt3L. 1mL of cells were plated in 6-well 
plate (Nunc, Roskilde, Denmark) and incubated at 37°C in a 5% CO2 humidified 
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incubator for 9 days without disturbing. A total of 2 x 105 Flt3-derived dendritic 
cells were plated in 200µl of complete RPMI medium in a 96-well plate. These 
cells were co-cultured with wildtype and recombinant lactobacilli at DC to 
bacteria (DCs:bacteria) ratio of 1:10 or 1:100. After 20-24 hours of stimulation, 
culture supernatants were collected for cytokine measurement by ELISA (section 
2.2.23).  
  
2.2.16 Animal immunization protocols 
2.2.16.1 Experiment I: In vivo immunogenicity study 
Four-week-old female C57BL/6 mice were fed with 1010 cfu of wildtype or 
recombinant lactobacilli via a gavage needle for 3 consecutive days per week over 
3 weeks. An additional control group of mice receiving 200 μl of PBS was 
included. Two days after the last feeding, the mice were sacrificed for T cell 
culture where cells were obtained from mesenteric lymph nodes and spleen. 
 
2.2.16.2 Experiment II: Prophylactic model 
Mice were fed with 1010 cfu of wildtype or recombinant lactobacilli as described 
in experiment I (section 2.2.16.1). An additional control group of mice receiving 
200 μl of PBS was included. Sixteen days after the last feeding, all mice were 
intraperitoneally injected with 10 μg Blo t 5 in 200 μl PBS containing 4 mg alum. 
Three weeks apart, all mice received second intraperitoneal injection of 5 μg Blo t 
5 in 200 μl PBS containing 4 mg alum. Two weeks later, mice were sacrificed. 
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Cells from mesenteric lymph nodes and spleen were collected for T cell culture. 
 
2.2.16.3 Experiment III: Allergic airway inflammation model 
Group of four mice were fed with 200 μl of PBS or 1010 cfu of wildtype or 
recombinant lactobacilli throughout the experiment. On day 3, a total of 2 x 106 
Blo t 5-specific Th2 cells in 150 μl of PBS were adoptively transferred into each 
mouse via tail vein injection. All mice were intranasally challenged with 50 μg of 
Blo t 5 in 50 μl of PBS for the following three consecutive days. Three weeks 
apart, all mice were intranasally challenged with 50 μg of Blo t 5 in 50 μl of PBS 
for 3 consecutive days. On the next day, the bronchoalveolar lavage fluids 
(BALF) were collected. 
 
2.2.17 Sera collection 
Blood was collected via retro-orbital bleeding weekly. Sera were collected for the 
measurement of Blo t 5-specific antibodies by ELISA (section 2.2.21 and 2.2.22). 
 
2.2.18 BALF collection and cytospin preparation 
Mice were deeply anesthetized by intraperitoneal injection with 300 μl mixture 
containing 7.6 mg/ml ketamine and 0.1 mg/ml medetomidine. The trachea was 
exposed and cannulated by tracheostomy (20-gauge cannula). The lung was 
lavaged 3 times with 0.8ml of ice-cold HBSS. BALF was centrifuged at 5000 rpm 
for 5 mins. Cells were washed with HBSS and finally resuspended in 200 μl 
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RPMI 1640 medium for total cell count.  
 
Cytospin was prepared by centrifugation of 1 x 105 cells in 100 μl of RPMI at 600 
rpm for 5 mins by using Cytospin 3 (Shandon, Runcorn, Cheshire, UK). The cells 
were stained with Liu stain (Liu CH, 1953). Cells were identified and 
differentiated into the following groups: macrophages/monocytes (mac/mono), 
lymphocytes (lym), neutrophils (neu) and eosinophils (eos) based on the standard 
morphological techniques under the light microscope. Five hundred of cells were 
counted for each lavage sample. The percentage of each cell type was calculated. 
 
2.2.19 Splenic and lymph nodes cell cultures 
Single cell suspension was obtained by disrupting the spleen or lymph nodes in 
HBSS using 2 frosted slides. Red blood cells were lysed by adding 1.5 ml of 
pre-warmed RBC lysis buffer (10 mM Tris, 0.83% NH4Cl, pH 8.3) for 90 secs. 
The cells were washed 3 times with HBSS and finally resuspended in complete 
RPMI 1640 medium. The cell number was determined by using a 
haemocytometer. To determine the cytokine production of freshly isolated splenic 
cells, a total of 4 x 105 splenocytes in 200 μl medium were stimulated in the 
presence of 10 μg/ml of Blo t 5 for 3 days in 96-well U bottomed plate (Nunc, 
Roskilde, Denmark). To determine the cytokine production of freshly isolated 
lymph nodes cells, 2 x 105 lymph node cells and 4 x 105 mitomycin C-treated 
antigen presenting cells (APCs) in 200 μl medium were stimulated in the presence 
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of 10 μg/ml Blo t 5 for 3 days. Culture supernatants were collected for cytokine 
measurement by ELISA (section 2.2.23). 
 
2.2.20 Preparation of antigen presenting cells  
Mitomycin-C treated splenocytes of naïve mice were used as APCs. Splenocytes 
were lysed with RBC lysis buffer, washed 3 times with HBSS and resuspended in 
PBS to a concentration of 5 x 107 cells/ml. Cells were treated with 50 μg/ml of 
Mitomycin-C in dark at 37°C waterbath for 20 mins. APCs were washed 3 times 
with HBSS and finally resuspended in complete RPMI medium.  
 
2.2.21 Detection of Blo t 5-specific IgE and IgG1 
The levels of Blo t 5 specific IgE and IgG1 were determined by Enzyme-Linked 
Immunosorbent Assay (ELISA). All samples were assayed in duplicates and 50 μl 
per well of reagents and samples were used unless otherwise stated. Briefly, 
96-well EIA/RIA plates (Costar, Corning, NY, USA) were coated with 2 μg/ml 
purified anti-Igκ mAb or 5 μg/ml Blo t 5 in 0.1 M sodium bicarbonate (pH 8.3; 
United States Biological, Swampscott, MA, USA) at 4°C overnight. Plates were 
washed 3 times with TBS-T using the automated Columbus washer (TECAN, 
Austria) and blocked with 100 μl of blocking buffer (1% BSA in TBS-T) at room 
temperature for 1 hour. Plates were washed 3 times with TBS-T and added with 
diluted or undiluted samples. For quantification purposes, 2-fold serial dilutions of 
purified IgE or IgG1 were added to the anti-Igκ mAb-coated wells. Plates were 
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incubated at 4°C overnight. Plates were washed 3 times with TBS-T and incubated 
with biotinylated monoclonal rat anti-mouse IgE and IgG1 at room temperature 
for 1 hour. Plates were washed 3 times with TBS-T and incubated with 
alkaline-phosphatase-conjugated ExtraAvidin at a dilution of 1:2000 (Sigma, St. 
Louis, MO, USA) at room temperature for 1 hour. Finally, plates were washed 6 
times with TSB-T and developed with Sigma Fast p-Nitrophenyl phosphatase 
substrate (pNPP; Sigma, St. Louis, MO, USA). Optical density was measured at 
405 nm by an ELISA microplate reader (Tecan, Ges.m.b.H, Austria). 
 
2.2.22 Mouse IgG2c quantitative ELISA 
The amounts of Blo t 5-specific IgG2c was detected by using the mouse IgG2c 
ELISA Quantification Kit according to the manufacturer’s instruction with minor 
modification. Briefly, 96-well EIA/RIA plates (Costar, Corning, NY, USA) were 
coated with 50 μl of 10 μg/ml purified goat anti-mouse IgG2c antibody or 5 μg/ml 
Blo t 5 in coating buffer (0.1 M NaHCO3, pH 8.3) overnight at 4°C. Plates were 
washed 3 times with TBS-T using the automated Columbus washer (TECAN, 
Austria) and blocked with 100 μl of blocking buffer (1% BSA in TBS-T) for at 
least 1 hour at room temperature. Plates were washed 3 times with TBS-T and 
added with diluted or undiluted samples. For quantification purposes, serial 
dilutions of mouse sera with known concentration of IgG2c standard were 
included. Plates were incubated at room temperature for 2 hours. After washing 
the plates 3 times with TBS-T, 50 μl of HRP-conjugated goat anti-mouse IgG2c 
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was added into each well. The plates were incubated at room temperature for 1 
hour. Plates were washed 6 times with TBS-T and signals were developed with 2, 
2'-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) substrate (ABTS; Sigma, St. 
Louis, MO, USA). Optical density was measured at 405 nm by an ELISA 
microplate reader (Tecan, Ges.m.b.H, Austria).  
 
2.2.23 Cytokine ELISA 
All samples were assayed in duplicates and 25 μl per well of reagents and samples 
were used unless otherwise stated. Briefly, 96-well ELISA plates were coated with 
purified antibodies to mouse IL-4 (BVD4-1D11; 1 μg/ml),   IL-5 (TRFK5; 2 
μg/ml), IL-6 (MP5-20F3; 0.5 μg/ml), IL-10 (JES052A5; 4 μg/ml), IL-12 
(48110.111; 2 μg/ml), IL-13(38213; 2 μg/ml), IFN-γ (R4-6A2; 2 μg/ml), TNF-α 
(AF-410-NA; 0.8 μg/ml) or TGF-β (A75-2.1; 2 μg/ml) in the coating buffer (0.1 
M NaHCO3, pH 8.3) and incubated at 4°C overnight. After washing 3 times with 
TBS-T, the plates were blocked with blocking buffer (1% BSA in TBS-T) at room 
temperature for 1 hour. Plates were washed 3 times with TBS-T and added with 
diluted or undiluted samples. For quantification purpose, recombinant mouse 
cytokines were prepared in 2-fold serial dilution in blocking buffer and included 
in each plate. The plates were incubated at 4°C overnight. The plates were washed 
3 times with TBS-T and incubated with biotin-conjugated rat anti-mouse IL-4 
(BVD6-24G2; 1.5 μg/ml), IL-5 (TRFK4; 2 μg/ml), IL-6 (MP5-32C11; 1 μg/ml), 
IL-10 (clone BAF417; 0.4 μg/ml), IL-12 (clone ; 2 μg/ml ), IL-13 (clone BAF413; 
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0.2 μg/ml), IFN-γ (XMG1.2; 2 μg/ml), TNF-α (clone BAF410; 0.3 μg/ml) and 
TGF-β (A75-3.1; 2 μg/ml) at room temperature for 1 hour. Plates were washed 3 
times with TBS-T and incubated with alkaline-phosphatase-conjugated 
ExtraAvidin (1:2000; Sigma, St. Louis, MO, USA) at room temperature for 1 
hour. Finally, plates were washed 6 times with TBS-T and developed with Sigma 
Fast p-Nitrophenyl phosphatase substrate (pNPP; Sigma, St. Louis, MO, USA). 
Optical density was determined at 405 nm on an ELISA microplate reader (Tecan, 
Ges.m.b.H, Austria). 
 
2.2.24 Statistical analysis 
Experimental data were expressed as mean ± standard Error of Mean (SEM). 
Statistical analysis was conducted using Student's t test. A P value of less than 0.05 
was taken as the level of significance. 
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Chapter 3 




In recent years, a substantial research effort has been devoted to the generation 
and modification of the expression vectors for the development of 
Lactobacillus-based vaccines for a number of diseases. To date, the commonly 
used inducible gene expression systems in lactobacilli are nisin-inducible 
expression vectors such as pNZ8037 (de Ruyter PG, 1996; Zhou XX, 2006; 
Daniel C, 2006; Rigaux P, 2009) and sakacin-inducible expression vectors such as 
pSIP400/500 series (Leer RJ, 1992; Axelsson L, 2003; Sørvig E, 2003; Mathiesen 
G, 2004; Sørvig E, 2005). Other expression vectors such as pLP400/500 vectors 
(Maassen CB, 1999; Pouwels PH, 2001; Ho PS, 2005; Kajikawa A, 2007; 
unpublished data our laboratory), pMEC vectors (Grangette C, 2001; Reveneau N, 
2002; Grangette C, 2002) as well as pMD112 (Scheppler L, 2002; Scheppler L, 
2005) have been evaluated and reported.  
 
Our laboratory has previously generated recombinant Lactobacillus casei strain 
Shirota expressing house dust mite allergens such as Blo t 5 or Der p 2 by using 
pLP402 expression system. However, the antigen expression levels were generally 
very low (unpublished data). The poor antigen expression in these recombinant 
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lactobacilli represents a major limiting factor for the vaccine development. Thus, 
this study aims to explore the use of an inducible expression system for the 
generation of recombinant lactobacilli with high levels of antigen expression.  
 
Lactic acid bacteria are known to produce two types of bacteriocins. The 
production of bacteriocins is often regulated via quorum-sensing mechanism 
based on a secreted peptide pheromone (Eijsink VGH, 2002; Quadri LE, 2002). 
The pheromone activates a two-component regulatory system consisting of a 
histidine kinase receptor and a cognate response regulator. Lantibiotics such as 
nisin is classified as class I bacteriocins. Lantibiotics itself acts as a pheromone 
that activates a two-component regulatory systems consisting of histidine kinase 
receptor and a cognate response regulator. Class II bacteriocins, such as sakacin A 
and sakacin P, produce and secrete a separate pheromone whose gene is usually 
co-transcribed with the genes encoding for the histidine kinase and the response 
regulator (Nes IF, 1999). In both cases, the activated response regulator enhances 
the transcription of all operons involved in the bacteriocin production.  
 
The nisin-controlled expression (NICE) system has been developed, based on the  
autoregulatory properties of Lactococcus lactis nisin gene cluster, where the 
combination of the nisA promoter and the nisRK regulatory genes. NICE system is 
one of the best characterised inducible expression systems for the use in lactococci 
and lactobacilli. The expression of desired protein is induced by the externally 
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added nisin. It allows efficient overproduction of heterologous proteins in 
lactococci (de Ruyter PG, 1996) and lactobacilli (Kleerebezem M, 1997; Pavan S, 
2000). However, it often exhibits significant basal activity and is poorly regulated 
in lactobacilli (Pavan S, 2000; Sørvig E, 2003). 
 
Similar systems have been developed on the basis of genes and promoters that are 
involved in the production of class II bacteriocins (Leer RJ, 1992; Axelsson L, 
2003; Sørvig E, 2003; Mathiesen G, 2004; Sørvig E, 2005). A series of “pSIP” 
expression vectors are constructed with a modular design that permits an easy 
exchange of all essential elements such as inducible promoter, cognate regulatory 
system, the gene of interest, antibiotics resistance marker and replicon (Sørvig E, 
2003; Mathiesen G, 2004; Sørvig E, 2005). These vectors differ in their 
bacteriocins regulon, regulated promoter and the replicon. The levels of protein 
expression of different vectors have been tested (Sørvig E, 2005). Among them, 
pSIP412 vector has been constructed with high copy number, broad-host-range 
SH71rep replicon (de Vos WM, 1987), PorfX promoter from sakacin P regulon and 
the cognate regulatory gene. The pSIP412 vector permits a controlled, 
considerable high-level expression of desired proteins in Lactobacillus sakei 
Lb790 and Lactobacillus plantarum NC8. This one-plasmid system not only 
keeps minimum background but also sustains the inducibility without integrating 
the genes into the host chromosome.  
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In the present study, pSIP412 was selected and evaluated for its inducible house 
dust mite allergen expression in Lactobacillus plantarum NC8 and Lactobacillus 
rhamnosus GG. The expression vector pSIP412 carrying the coding sequence of 
mature Blo t 5 was constructed and finally introduced it into Lactobacillus 
plantarum NC8 and Lactobacillus rhamnosus GG. The expression levels of Blo t 
5 in recombinant Lactobacillus plantarum NC8 (rLp) and recombinant 
Lactobacillus rhamnosus GG (rLGG) were assessed by biochemical and 
densitometric methods. The immunomodulatory effects of these recombinant 
lactobacilli on dendritic cell maturation were assessed by phenotypic changes and 
cytokine production profiles of dendritic cells (DCs). In addition, the capability of 
recombinant lactobacilli-pulsed DCs to present antigen to antigen-specific T cells 




3.2.1 Purification of recombinant Blo t 5 from Pichia pastoris culture media 
Recombinant Blo t 5 (rBlo t 5) protein was purified from the culture medium of 
the recombinant Pichia pastoris expressing Blo t 5 using the hydrophobic 
interaction and anion exchange chromatography as described in section 2.2.1. The 
purified yeast recombinant Blo t 5 protein was shown as a single band with an 
estimated molecular weight of about 14 kDa on a SDS-PAGE (Figure 3.1A). 
Western blot analysis showed that this band was specifically recognised by a Blo t  
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5-specific monoclonal antibody (mAb) 4A7 (Figure 3.1B). The estimated yield of 
recombinant Blo t 5 was estimated at 20 mg/L with the flask-culture method. The 




























































Figure 3.1 Characterization of recombinant Blo t 5 produced from Pichia 
pastoris. The purified recombinant Blot 5 protein was analyzed by SDS-PAGE. The 
amounts of protein loaded (μg) were indicated (A). The purified recombinant Blo t 5 
was reacted with a monoclonal anti-Blo t 5 antibody 4A7 by Western blot (B). Arrows 
indicate the position of the recombinant Blo t 5 (~14 kDa). M: molecular mass 
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3.2.2 Construction and transformation of pSIP412-Bt5 into lactobacilli. 
The construction of recombinant plasmid pSIP412-Bt5 is schematically shown in 
Figure 2.1. As intact plasmids were necessary for successful transformation of 
most Lactobacillus strains (Maassen CB, 1999; Fuller R, 2000), Lactococcus 
lactis cremoris MG1363 was therefore used as an intermediate host for the 
plasmid propagation. The stepwise transformation procedures are summarised in 
Figure 2.2. Briefly, the pSIP412 plasmid DNA (8,405 bp) was digested with NcoI, 
treated with Klenow polymerase and further digested with XhoI to remove the 
aminopeptidase N (pepN) reporter gene (2,553 bp). The resulting plasmid (5,852 
bp) was ligated with XhoI-digested cDNA encoding for mature Blot 5 (~351 bp). 
The pSIP412 plasmid DNA or ligation mixture was transformed into the 
immediate host Lactococcus lactis cremoris MG1363 (section 2.2.6). The 
pSIP412 and pSIP412-Bt5 plasmid DNA were extracted from the Lactococcus 
lactis cremoris MG1363 transformants and subsequently linearised with 
restriction enzyme XhoI. The fully linearized pSIP412 (~8.4 kb) and pSIP412-Bt5 
(~6.2 kb) plasmid DNA were analysed on a 0.8% agarose gel (Figure 3.2A). 
Screening of the pSIP412-Bt5 containing Lactococcus lactis cremoris MG1363 
transformants was performed by PCR method using the Blo t 5-specific primers 
(section 2.2.5). Recombinant plasmid pGEX-4T1-Bt5 was included as a positive 
experimental control. The result showed that cDNA encoding the mature Blo t 5 
was successfully inserted into the pSIP412-Bt5 (Figure 3.2B). The nucleotide 
sequences of the pSIP412-Bt5 construct were further confirmed by DNA 
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sequencing. Recombinant plasmid pSIP412-Bt5 was finally transformed into 
Lactobacillus plantarum NC8 and Lactobacillus rhamnosus GG (LGG) by 

























































Figure 3.2 Analysis of pSIP412-Bt5 construct. (A) pSIP412 (8,405 bp) and 
pSIP412-Bt5 (6,208 bp) which were extracted from the intermediate host Lactococcus 
lactis subspecies cremoris MG1363 were digested with XhoI. Arrows indicate the 
bands of linearized pSIP412 and pSIP412-Bt5. (B) Polymerase chain reaction 
amplification of Blo t 5 coding sequence from extracted plasmids by using the Blo t 5 
specific primers. Arrow indicates the band of the Blo t 5 coding fragment (~351 bp). 
M: hundred base pair (bp) DNA ladders; Lane 1, pSIP412 extracted from Lactococcus 
lactis; Lane 2, pSIP412-Bt5 extracted from Lactococcus lactis; Lane 3, pGEX-4T1-
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3.2.3 Expression kinetics of Blo t 5 in recombinant lactobacilli 
The Blo t 5 expression in recombinant Lactobacillus plantarum NC8 and 
recombinant LGG was induced by an addition of Sakacin P inducing peptide 
(SppIP) to bacterial cultures when the OD600 reached 0.3. The protein expression 
kinetics of Blo t 5 in recombinant Lactobacillus plantarum NC8 and recombinant 
LGG were monitored using samples taken at OD600 of 0.6, 1.2 and 2.0. The results 
were shown in Figure 3.3A and 3.3B, respectively. The expression levels of Blo t 
5 in both recombinant lactobacilli increased in a time-dependent manner. Notably, 
the level of Blo t 5 expressed in recombinant Lactobacillus plantarum NC8 was 
relatively higher than that of the recombinant LGG.  
To further confirm the expression of Blo t 5 in recombinant Lactobacillus 
plantarum NC8 and recombinant LGG, western blot was performed by using 
ascites fluid containing mAb 4A7 (Yi FC, 2005). As shown in Figure 3.4, mAb 
4A7 reacted strongly with a protein of molecular weight of about 14 kD in both 
recombinant Lactobacillus plantarum NC8 and recombinant LGG, confirming 
that a monomeric form of Blo t 5 protein was indeed successfully expressed in 
these recombinant lactobacilli. A weak band with an estimated size of 28 kDa was 
also observed in the SppIP-induced culture of recombinant Lactobacillus 
plantarum NC8. This band may represent a dimer of Blo t 5. Uninduced culture 
samples of recombinant Lactobacillus plantarum NC8 and recombinant LGG 













































Figure 3.3 Kinetics of Blo t 5 expression in recombinant lactobacilli. 
Recombinant Blo t 5 expressed in Lactobacillus plantarum (A) and Lactobacillus 
rhamnosus GG (B) were analyzed by Coomassie blue-stained SDS-PAGE gel. Blo t 5 
expression was induced by Sakacin P inducing peptide (SppIP) when OD600 reached 
0.3. After the addition of Sakacin P inducing peptide, cultures of recombinant 
lactobacilli were sampled at indicated OD600 values. The cultures of recombinant 
lactobacilli without Sakacin P inducing peptide were included as controls. The gel 
loading of each lane was corresponding to 100 µl of bacterial culture. Arrows indicate 




75   - 
 
50   - 
 
37   - 
 
25   - 
 
20   - 
 
15   - 
 
10   - 
 
 0.3  0.6  1.2   2.0    0.6  1.2  2.0    OD600 
(kDa)   M      -      -      -      -      +     +      +     SppIP 
97   - 
 
66   - 
 
45   - 
 
31   - 
 
21   - 
 
14.4 - 
 0.3   0.6   1.2   2.0    0.6  1.2  2.0    OD600 















































Figure 3.4 Western blot analysis of Blo t 5 expressed in recombinant 
lactobacilli. Recombinant Blo t 5 expressed in Lactobacillus plantarum (rLp) and 
Lactobacillus rhamnosus GG (rLGG) were analyzed by probed with monoclonal anti-
Blo t 5 antibody 4A7. Blo t 5 expression was induced by Sakacin P inducing peptide 
(SppIP) when the OD600 reached 0.3. After 4 hours, 1 ml of cultures were collected 
from the induced and the non-induced cultures of recombinant lactobacilli. The gel 
loading of each lane was corresponding to 100 µl of bacterial culture. Arrows indicate 
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3.2.4 Quantification of Blo t 5 in recombinant lactobacilli  
To quantitate the amount of Blo t 5 expressed by recombinant Lactobacillus 
plantarum NC8 and recombinant LGG, western blot and densitometric analysis 
were performed (Figure 3.5A). Three doses of cell lysates containing the indicated 
colony formation units (cfu) of recombinant Lactobacillus plantarum NC8 (1x106, 
2x106 and 3x106 cfu) and recombinant LGG (2x106, 4x106 and 8x106 cfu) were 
used for western blot analysis with ascites fluid. Densitometric analysis was 
performed on gel image captured using LAS-3000. The band density was 
measured as arbitrary unit (AU). Based on the known amounts (20, 40 and 80 ng) 
of rBlo t 5, a reference curve of Blo t 5 quantities (y-axis) versus AU (x-axis) was  
constructed to convert the amounts of Blo t 5 expressed in recombinant 
lactobacilli (Figure 3.5B). The estimated amounts of Blo t 5 expressed by 1010 cfu 
of recombinant Lactobacillus plantarum NC8 and recombinant LGG were 
approximately 400 and 150 µg, respectively (Table 3.1). The amount of Blo t 5 
expressed by recombinant LGG was about 2.5-fold lower than that of the 
recombinant Lactobacillus plantarum NC8. The lower level of protein expression 
in recombinant LGG could be due to a number of factors such as mRNA stability, 
codon usage of the protein, host cell physiology and potential negative effects of 
the protein on the host cell (Sorvig E, 2005). A further experiment was carried out 
to determine whether the lower level of Blo t 5 expression was correlated to poor 
protein stability. In this experiment, the Blo t 5 expression in recombinant LGG 
was induced by Sakacin P. After 4-hour of induction, bacteria were washed and 
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grown in MRS broth without Sakacin P for another twenty hours. Western blot 
analysis showed that Blo t 5 was stable in recombinant LGG for at least up to 


























































Figure 3.5 The quantification of Blo t 5 expression in recombinant lactobacilli. 
(A) Cell lysates containing the indicated colony formation units (cfu) of recombinant 
Lactobacillus plantarum NC8 (rLp) and recombinant Lactobacillus rhamnosus GG 
(rLGG) were separated in 7.5% SDS-PAGE and further analyzed by Western blot. 
Arrows indicate the position of Blo t 5 (~14 kDa). The purified Blo t 5 protein was 
used as standards for the indicated amounts. The gel image was captured by the 
FujiFilm LAS-3000. The band density was measured and expressed as AU units. M: 
molecular mass markers (kDa). (B) A reference curve of Blo t 5 quantities (y-axis) 
versus AU units (x-axis) was used to convert the amounts of Blo t 5 expressed in 
recombinant Lactobacillus plantarum NC8 (▲) and recombinant Lactobacillus 
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Bacteria strains Blo t 5 amount / 1 × 1010 cfu 
Recombinant Lactobacillus plantarum NC8 (rLp) 400 μg 










































Figure 3.6 The stability of Blo t 5 produced in Lactobacillus rhamnosus GG. 
Blo t 5 expression was induced by Sakacin P inducing peptide (SppIP) when the 
OD600 reached 0.3. After 4-hour of induction, the bacteria were washed and cultured 
in MRS broth without Sakacin P inducing peptide for 20 hours. Samples of 1 ml of 
bacterial cultures were harvested at 1 hour (lane 2), 2 hours (lane 3), 3 hours (lane 4), 
4 hours (lane 5), 5 hours (lane 6) and 20 hours (lane 7) after withdrawing the Sakacin 
P inducing peptide from the culture medium. Bacterial cell lysates were separated on 
7.5% SDS-PAGE and subjected to Western blotting probed with monoclonal anti-Blo 
t 5 antibody 4A7. The gel loading of each lane was corresponding to 100 µl of the 
bacterial culture. Arrows indicate the position of Blo t 5 (~14 kDa). Lane 1: 150 ng of 
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3.2.5 The immunomodulatory effect of recombinant lactobacilli on murine 
bone marrow-derived dendritic cells (BMDCs) 
To determine the immunomodulatory effects of recombinant lactobacilli on 
BMDCs, the maturation of BMDC was assessed by the surface marker expression 
and cytokine production profiles. In this experiment, BMDCs were co-cultured 
with recombinant Lactobacillus plantarum NC8 or recombinant LGG at  
DCs:bacteria ratio of 1:10 or 1:100 for 20-24 hours. Unpulsed BMDCs, BMDCs 
pulsed with 1 μg/ml of lipopolysaccharide (LPS) or 10 μg/ml of Blo t 5 or 
wildtype lactobacilli or wildtype lactobacilli plus Blo t 5 were included as 
controls. 
 
3.2.5.1 The expression profiles of surface markers on BMDCs 
Pulsed BMDCs were stained with specific antibodies for CD86, MHC class II 
I-Ab, CD40, CD80 and CD11c for flow cytometric analysis. As compared to the 
unpulsed BMDCs, LPS, but not the exogeneous Blo t 5 protein, induced the 
maturation of BMDCs as shown by the upregulation of CD86, MHC class II I-Ab, 
CD40 and CD80 expression (Figure 3.7A). At both DCs:bacteria ratios of 1:10 
and 1:100, all the lactobacilli-pulsed DCs displayed similar surface expression 
profiles of MHC class II I-Ab, CD40 and CD80 with the exception of CD86 
(Figure 3.7B, 3.7C, 3.7D and 3.7E). The expression of the CD86 molecules was 
further upregulated when the DCs:bacteria ratio was raised from 1:10 to 1:100. No 
differences in the surface marker expression profiles of BMDCs were observed 
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when BMDCs were pulsed with wildtype lactobacilli alone or in combination with 
exogeneous Blo t 5 protein (data not shown). 
 
3.2.5.2 The cytokine production by BMDCs 
The levels of cytokines produced by pulsed BMDCs in the culture supernatants 
were measured by ELISA. The results showed that LPS-pulsed BMDCs produced 
significant levels of IL-10, IL-12, IL-6 and TNF-α whereas the unpulsed BMDCs 
only produced low basal levels of these cytokines (Figure 3.8). Interestingly, 
significant high levels of IL-10, IL-12, TNF-α and IL-6 were produced by the 
recombinant LGG-pulsed BMDCs as compared to that of the recombinant 
Lactobacillus plantarum NC8-pulsed BMDCs at DCs:bacteria ratio of 1:10 or 
1:100. The level of IL-10 was significantly higher in wildtype LGG-pulsed 
BMDCs than recombinant LGG- and wildtype Lactobacillus plantarum 
NC8-pulsed BMDCs at both DCs:bacteria ratios (Figure 3.8A). On the other hand, 
the level of IL-12 was significantly higher in both recombinant lactobacilli-pulsed 
BMDCs than that of the both wildtype lactobacilli-pulsed BMDCs at 1:100 
DCs:bacteria ratio (Figure 3.8B). The levels of TNF-α and IL-6 produced by all 




















Figure 3.7 The phenotypes and maturation status of murine bone-marrow 
derived dendritic cells (BMDCs) co-cultured with recombinant lactobacilli. The 
immature BMDCs were co-cultured with wildtype or recombinant lactobacilli for 20-
24 hours and the cell surface markers CD86, MHC class II I-Ab, CD40, CD80 and 
CD11c were analyzed with flow cytometry. DCs with medium alone (filled grey 
histograms), LPS-stimulation (open green histograms) and Blo t 5-stimulation (open 
blue histograms) were included as references (A). 1 x 106 of BMDCs were stimulated 
with wildtype Lactobacillus plantarum (B), recombinant Lactobacillus plantarum (C), 
wildtype LGG (D) and recombinant LGG (E) at the DCs:bacteria ratio of 1:10 (open 
grey histograms) or 1:100 (open red histograms). The numbers on top of each 
histogram represent the geometric means. 
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Figure 3.8 The cytokine production of murine bone-marrow derived dendritic 
cells (BMDCs) co-cultured with recombinant lactobacilli. 1 x 106 of BMDCs were 
co-cultured with recombinant Lactobacillus plantarum (rLp) or recombinant 
Lactobacillus rhamnosus GG (rLGG) at the DCs:bacteria ratio of 1:10 (  ) or 1:100 
(   ). Medium alone (none), lipopolysaccharide (LPS) and wildtype lactobacilli (wtLp 
or wtLGG) were included as controls. Culture supernatants were collected after 20-24 
hours of incubation. The levels of IL-10 (A), IL-12 (B), TNF-α(C) and IL-6 (D) were 
measured by enzyme-linked immunosorbent assays. Data are presented as mean ± 
standard error of mean. *: p < 0.05; **: p < 0.01. 
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3.2.6 The effects of recombinant lactobacilli on cytokine production by 
murine Flt3-derived dendritic cells  
The immunomodulatory effects of recombinant lactobacilli on Flt3-derived DCs 
were evaluated. LPS- and lactobacilli-pulsed Flt3-derived DCs were capable of 
producing substantial amounts of IL-10, IL-12, IL-6 and TNF-α, but the levels of 
IL-10 and IL-6 production were relatively lower as compared to that of BMDCs 
(Figure 3.9). Unlike the BMDCs, Flt3-derived DCs pulsed with lactobacilli did 
not induce IL-6 production at DCs:bacteria ratio of 1:10 (Figure 3.9D). Notably, 
the IL-10 levels produced by recombinant Lactobacillus plantarum NC8-pulsed 
Flt3-derived DCs were significantly lower than that of the wildtype Lactobacillus 
plantarum NC8- and recombinant LGG-pulsed Flt3-derived DCs (Figure 3.9A). 
The IL-12 level produced by recombinant Lactobacillus plantarum NC8-pulsed 
Flt3-derived DCs was only found significantly lower than that of the wildtype 
Lactobacillus plantarum NC8- and recombinant LGG -pulsed Flt3-derived DCs at 
a DCs:bacteria ratio of 1:100 (Figure 3.9B). As compared to the wildtype 
Lactobacillus plantarum NC8-pulsed Flt3-derived DCs, wiltype LGG-pulsed 
Flt3-derived DCs produced significant high levels of IL-10 and IL-12 at 
DCs:bacteria ratio of 1:100 (Figure 3.9A and 3.9B). 
 
Taken together, the levels of all cytokines tested in BMDCs and Flt3-derived DCs 
were profoundly higher in LGG strain than Lactobacillus plantarum NC8 strain. 
These findings implied that LGG and Lactobacillus plantarum NC8 possess 
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distinct adjuvant properties and induce differential immunomodulation on 




















































































































































































































































Figure 3.9 The cytokine production of murine Flt3-derived dendritic cells co-
cultured with recombinant lactobacilli. 2 x 105 of Flt3-derived DCs were co-
cultured with recombinant Lactobacillus plantarum (rLp) or recombinant 
Lactobacillus rhamnosus GG (rLGG) at the DCs:bacteria ratio of 1:10 (   ) or 1:100 
(  ). Medium alone (none), lipopolysaccharide (LPS) and wildtype lactobacilli (wtLp 
or wtLGG) were included as controls. Culture supernatants were collected after 20-24 
hours of incubation. The levels of IL-10 (A), IL-12 (B), IL-6 (C) and TNF-α (D) were 
measured by enzyme-linked immunosorbent assays. Data are presented as mean ± 
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3.2.7 Induction of antigen-specific T cell activation by recombinant 
lactobacilli pulsed-murine BMDCs  
In order to determine whether the recombinant lactobacilli-pulsed BMDCs can 
serve as competent antigen presenting cells (APCs) to induce the antigen-specific 
T cell activation, Blo t 5-specific T cells were co-cultured with recombinant 
lactobacilli-pulsed BMDCs and the T cell proliferation as well as the cytokine 
production by these specific T cells were assessed. In this experiment, BMDCs 
were pulsed with recombinant Lactobacillus plantarum NC8 and recombinant 
LGG at DCs:bacteria ratio of 1:10 or 1:100 for 20-24 hours. Pulsed BMDCs were 
harvested and co-cultured with Blo t 5-specific T cells at DC:T ratio of 0.2:1 or 
1:1 for 3 days. Unpulsed, LPS-, Blo t 5-, wildtype lactobacilli- and wildtype 
lactobacilli plus exogeneous Blo t 5-pulsed BMDCs were included as controls.  
 
3.2.7.1 The proliferation of Blo t 5-specific T cells 
Under the culture condition of 1:1 DC:T ratio, Blo t 5-pulsed BMDCs, but not the 
unpulsed BMDCs, induced Blo t 5-specific T cell proliferation (Figure 3.10A). 
Notably, BMDCs pulsed with the wildtype lactobacilli plus exogeneous Blo t 5- 
and recombinant lactobacilli strongly induced Blo t 5-specific T cell proliferation 
that was at least three-fold higher than that of the Blo t 5-pulsed BMDCs. 
Wildtype lactobacilli- and LPS-pulsed BMDCs failed to induce any Blo t 
5-specific T cell proliferation. Under the culture condition of 0.2:1 DC:T ratio, 
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similar results were obtained with reduced levels of T cell proliferation (Figure 
3.10B). 
 
3.2.7.2 The cytokine production by Blo t 5-specific T cells 
The Blo t 5-specific T cells used in this study are Th2-type cells. Upon the 
activation of Blo t 5 protein, these specific T cells are capable of producing 
signature Th2 cytokines such as IL-4, IL-5, IL-10 and IL-13. Blo t 5-pulsed 
BMDCs, but not the unpulsed BMDCs, induced the cytokine production by Blo t 
5-specific T cells (Figure 3.11). Under the culture condition of 1:1 DC:T ratio, 
wildtype lactobacilli plus exogenous Blo t 5- and recombinant lactobacilli-pulsed 
BMDCs led to higher cytokine production by Blo t 5-specific T cells. Wildtype 
lactobacilli- and LPS-pulsed BMDCs failed to induce cytokine production by 
these specific T cells. Similar experiments performed at DC:T ratio of 0.2:1 gave 
similar results with reduced levels of cytokine production by the activated T cells 
(data not shown).  
 
These data clearly demonstrated that murine BMDCs could efficiently uptake the 
Blo t 5-expressing recombinant lactobacilli, process and subsequently present Blo 
t 5 to the Blo t 5-specific T cells as indicated by the high levels of T cell 





















































































































Figure 3.10 Recombinant lactobacilli-pulsed bone-marrow derived dendritic 
cells (BMDCs) induced the proliferation of a Blo t 5-specific T cells. BMDCs were 
pulsed with recombinant Lactobacillus plantarum (rLp) or recombinant Lactobacillus 
rhamnosus GG (rLGG) at the DCs:bacteria ratio of 1:10 (  ) or 1:100 (  ) for 20-24 
hours. Unpulsed-, lipopolysaccharide (LPS)-, Blo t 5-, wildtype lactobacilli (wtLp or 
wtLGG)- and wildtype lactobacilli plus Blo t 5 (wtLp+Bt5 or wtLGG+Bt5)-pulsed 
DCs were included as controls. Different stimuli-pulsed BMDCs were harvested, 
washed and co-cultured with a Blo t 5-specific T cells (5 x 104 per well) at the DCs:T 
cells ratio of 1:1 (A) or 0.2:1 (B). Blo t 5-specific T cell proliferation was measured 
by the [3H]-thymidine incorporation on day 3. Each well was added with 1 μCi of 
[3H]-thymidine for the last 20 hours of culture. cpm, counts per minute. 
 

































































































































































































Figure 3.11 Recombinant lactobacilli-pulsed bone-marrow derived dendritic 
cells (BMDCs) induced the cytokine production of Blo t 5-specific T cells. 
BMDCs were pulsed with recombinant Lactobacillus plantarum (rLp) or recombinant 
Lactobacillus rhamnosus GG (rLGG) at the DCs:bacteria ratio of 1:10 (   ) or 1:100 (  )  
for 20-24 hours. Unpulsed-, lipopolysaccharide (LPS)-, Blo t 5-, wildtype lactobacilli 
(wtLp or wtLGG)- and wildtype lactobacilli plus Blo t 5 (wtLp+Bt5 or wtLGG+Bt5)-
pulsed DCs were included as controls. Pulsed BMDCs were harvested, washed and 
co-cultured with a Blo t 5-specific T cells (5 x 104 per well) at the DCs:T cells ratio of 
1:1. Culture supernatants were collected on day 3 for the measurement of IL-4 (A), 
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3.3 Discussion 
For the development of an effective antigen-expressing Lactobacillus-based oral 
vaccine, several parameters such as the choice of Lactobacillus strain, the amount 
and localisation of antigen expressed have to be taken into consideration. Firstly, 
the proper selection of Lactobacillus strains is crucial. Although dietary 
Lactobacillus strains with GRAS status are generally safe for human oral 
consumption, different Lactobacillus strains possess differential intrinsic 
adjuvanicity (Maassen CB, 2000). They differ in their cell-wall components, 
soluble factors, genomic DNA, physiology and behavior in the gastrointestinal 
tract, thereby affecting their immunogenicity and the induction of systemic 
immune responses. Previous published studies have suggested that Lactobacillus 
plantarum could be a potent Th1 inducer (Murosaki S, 1998; Hessle C, 1999; 
Repa A, 2003) whereas LGG could be a potent Treg inducer (Feleszko W, 2007). 
Based on their reported differential intrinsic adjuvant properties, the side by side 
comparative studies on recombinant Lactobacillus plantarum NC8 and 
recombinant LGG were performed to evaluate their potential exploitation as a live 
vector for antigen delivery as well as an adjuvant to enhance antigen-specific 
adaptive immunity. This study paves the way for the development of an 
antigen-based oral vaccine for allergic diseases such as asthma.   
 
In addition to the choice of Lactobacillus strains, the cellular location of the 
antigen expressed affects the immunogenicity of the recombinant lactobacilli. The 
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intracellular production of protein might be more efficient in the induction of 
specific immune responses than the cell surface-anchored protein (Norton PM, 
1996). The oral delivery of tetanus toxin fragment C (TTFC) expressed as an 
intracellular antigen was more effective than cell-surface expression (Shaw DM, 
2000). Conversely, cell surface-anchored antigen has been reported to be more 
immunogenic than intracellularly expressed antigen and secreted antigen (Dieye Y, 
2003; Bermúdez-Humarán LG, 2004). However, the surface antigen expression 
may be more susceptible to low pH, bile acid or proteolytic environments 
encountered by vaccine vectors following mucosal immunisation. Therefore, the 
best location of an expressed antigen for an optimal mucosal immunisation 
remains unclear and deserves more studies.   
 
Depending on the immunogenicity of the antigen and the immunisation regime, a 
specific threshold for the amount of expressed antigen is required to elicit an 
immune response (Zegers ND, 1999; Grangette C, 2001; Grangette C, 2002; 
Reveneau N, 2002; Seegers JF, 2002; Adel-Patient K, 2005; Wells JM, 2008). It 
has been reported that no specific antibody response against protective antigen 
(PA) of Bacillus anthracis was detected probably due to the low intracellular 
production of PA by using pLP503 expression vector (Zegers ND, 1999). In 
addition, recombinant Lactobacillus strains expressing TTFC failed to elicit 
specific antibody response (Grangette C, 2001; Grangette C, 2002). Reveneau N 
et al. has demonstrated that the highest specific antibody levels were obtained 
 90
with the strains producing high intracellular levels of TTFC (Reveneau N, 2002). 
These findings suggested that the expression level of the intracellular protein is 
critical in the induction of antigen-specific immune responses. 
 
This study was the first to describe the use of Sakacin P-inducible expression 
vector pSIP412 in Lactobacillus plantarum NC8 or LGG as a host for the 
expression of a major house dust allergen, Blo t 5. It is well established that the 
Sakacin P-inducible expression system could produce high levels of tested 
antigens in Lactobacillus plantarum NC8 (Sørvig E, 2005), but there is no 
published report on the evaluation of this expression system in LGG to date. 
Therefore, the main focus of this study aimed to perform a systematic comparative 
evaluation of this expression vector system in two Lactobacillus stains. The 
expression level of Blo t 5 in recombinant LGG was nearly 2.7-fold lower than in 
recombinant Lactobacillus plantarum NC8 (Table 3.1). Notably, Blo t 5 was 
expressed stably in the recombinant LGG up to twenty hours post-induction 
(Figure 3.6). With the use of nisin-inducible pNZ8037 expression system, Daniel 
C et al. has reported that 1010 cfu of recombinant Lactococcus lactis and 
recombinant Lactobacillus plantarum expressed 4 and 16 µg of Bet v1, 
respectively. In the current study, the amount of Blo t 5 antigen expressed was at 
least 10-fold higher by using SppIP-inducible pSIP412 expression system as 
compared to the nisin-inducible pNZ8037 expression system (Daniel C, 2006). In 
addition, Kajikawa A et al. has reported that 1010 cfu of recombinant Lactococcus 
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casei expressing less than 5 µg of flagellin failed to induce antigen-specific 
antibody production (Kajikawa A, 2007). Furthermore, the amounts of Blo t 5 
expressed in recombinant Lactobacillus plantarum NC8 and recombinant LGG by 
using pSIP412 expression vector were much higher than that using pLP402 
expression vector (unpublished data from our laboratory). These findings 
suggested that pSIP412 represents a better expression vector system for Blo t 5 
antigen expression in both Lactobacillus strains, therefore greatly facilitating 
further development of the Lactobacillus-based oral vaccine for allergic diseases. 
 
Dendritic cells are professional antigen presenting cells (APCs) that prime and 
direct the differentiation of naïve T cells into Th1, Th2 or Treg cell subsets 
(Banchereau J, 1998). DC maturation is necessary for both Th1 and Th2 cell 
differentiation (Kaliński P, 1999) and T cell tolerance requires certain degree of 
DC maturation (Perez VL, 1997; Albert ML, 2001; Figdor CG, 2004). The 
DC-derived cytokines is the most important factor in shaping the T cell responses 
(Mazzoni A, 2004). IL-12-producing DCs promotes the polarisation of 
IFN-gamma producing Th1 cells (Trinchieri G, 1994; Macatonia SE, 1995). IL-10 
is a pleiotropic cytokine, which promotes Th2 cell development (Stumbles PA, 
1998; Iwasaki A, 1999). In contrast, IL-10-producing DCs may promote the 
generation of T regulatory cells with an immunosuppressive function (Wakkach A, 
2003; Mocellin S, 2004). IL-10 has also been shown to inhibit the production of 
IL-12 by Th1 cells (Yang X, 1999; Moore KW, 2001).   
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In the present study, both wildtype lactobacilli and recombinant lactobacilli could 
induce BMDC maturation by upregulating the surface expression of CD80, CD86, 
CD40 and MHC class II I-Ab on BMDC (Figure 3.7) as well as the production of 
IL-12, IL-10, IL-6 and TNF-α (Figure 3.8). The surface marker expression 
profiles and cytokine production were found relatively similar among the same 
Lactobacillus strains, suggesting that the genetic transformation of Lactobacillus 
plantarum NC8 and LGG does not modify their intrinsic adjuvanicity in the DC 
immunomodulation. Interestingly, both wildtype LGG- and recombinant 
LGG-pulsed BMDCs significantly induced higher levels of IL-10 and IL-12 
production as compared to that of wildtype Lactobacillus plantarum NC8- and 
recombinant Lactobacillus plantarum NC8-pulsed BMDCs (Figure 3.8A and 
3.8B). Similar profiles with lower levels of cytokine production are observed in 
Flt3-derived DCs pulsed with either wildtype or recombinant Lactobacillus strain 
(Figure 3.9). Taken together, these results suggested that the Lactobacillus strains 
could modulate the cytokine production by murine DCs in a strain-dependent 
manner. 
 
Akbari O et al. has reported that the pulmonary dendritic cells (DCs) from mice 
exposed to respiratory antigen transiently produced IL-10. These IL-10-producing 
DCs were phenotypically mature and migrate to the draining lymph nodes to 
stimulate the antigen-specific Tregs (Akbari O, 2001). In addition, mice lacking 
IL-10 exhibited spontaneous enterocolitis and exaggerated asthmatic and allergic 
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responses (Kuhn R, 1993). Based on these published data, the findings derived 
from this study denoted the possibility of recombinant LGG expressing Blo t 5 in 
the induction of IL-10-producing tolerogenic DCs which eventually drive to the 
antigen-specific Treg cell development. However, the immunological 
consequences of the relatively high IL-10 production by LGG-pulsed DCs 
remains to be further elucidated. 
 
On the other hand, Lactobacillus plantarum was previously reported as a potent 
inducer of IL-12, directing the Th1 cell development (Murosaki S, 1998; Hessle C, 
1999; Repa A, 2003). It might have the capacity to switch the established Th2 
response in mite allergic patients towards Th1 response by inducing the 
production of IL-10 and IL-12 by monocyte-derived DCs from allergic patients 
(Pochard P, 2005). However, it appeared that wildtype and recombinant 
Lactobacillus plantarum NC8 tested in this study induced lower levels of IL-10 
and IL-12 production by pulsed-DCs as compared to that of the LGG strain. The 
discrepancy in the findings between this study and the published data could be due 
to the differential adjuvant properties exhibited by the different sub-strains of 
Lactobacillus plantarum. For example, the levels of IL-12p70 produced by murine 
splenocytes from ovalbumin (OVA)-sensitised mice stimulated with OVA in the 
presence of Lactobacillus plantarum JCM 1149 and Lactobacillus plantarum 
MEP170401 were 39 and 4,907 pg/ml, respectively (Sashihara T, 2006). These 
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results suggested that different Lactobacillus substrains may possess their own 
intrinsic adjuvant properties.  
 
Moreover, all wildtype and recombinant lactobacilli tested induced the production 
of TNF-α and IL-6 by the pulsed-BMDCs. The activation NF-κB via Toll-like 
receptors on the surface of DCs leads to the production of TNF-α 
proinflammatory cytokine (Medzhitov R, 2001). On the other hand, IL-6 is mainly 
produced by APCs. It has been reported that IL-6 promotes terminal 
differentiation of B cells into plasma cells, induces Th2 cell polarisation (Rincón 
M, 1997), and enhances the intestinal IgA response (McGhee JR, 1991; Ramsay 
AJ, 1994; Braciak TA, 2000). However, unlike IL-10 and IL-12, the precise roles 
of these two cytokines in the innate immunity are relatively unknown, thus the 
possible immunological impacts of IL-6 and TNF-α produced by 
lactobacilli-pulsed DCs remains to be elucidated.  
 
Interestingly, the data on the T cell activation indicated that Blo t 5-expressing 
recombinant lactobacilli pulsed-BMDCs induced significantly higher levels of T 
cell proliferation and cytokine production as compared to that of the BMDCs 
pulsed with exogenously added Blo t 5 protein alone or in the combination of 
wildtype lactobacilli. Immature DCs uptake antigen by three ways: phagocytosis, 
macropinocytosis or adsorptive pinocytosis (Banchereau J, 1998). Immature DCs 
can uptake particles and microbes via phagocytosis (Inaba K, 1993; Svensson M, 
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1997). They can also form large pinocytic vesicles in which extracellular fluid and 
solutes are sampled, where a process called macropinocytosis (Sallusto F, 1995). 
They can also express receptors that mediate adsorptive endocytosis (Sallusto F, 
1994; Sallusto F, 1995; Jiang W, 1995). At any rate, bacterium-associated antigen 
was presented with higher efficiency than soluble antigen by B cells, indicating 
that phagocytosis represents a very effective mechanism for providing antigens to 
the MHC class II processing pathway in different APC types (Vidard L, 1996; 
Inaba K, 1998; Corinti S, 1999). Therefore, it appeared that the pulsed-BMDCs 
could be more efficient in uptaking the Blo t 5-expressing recombinant lactobacilli 
and subsequently present Blo t 5 to the Blo t 5-specific T cells as compared to the 
BMDCs pulsed with exogeneous Blo t 5 protein alone. Notably, recombinant 
Lactobacillus plantarum NC8-pulsed BMDCs have led to higher specific T cell 
proliferation and cytokine production by these specific T cells as compared to that 
of the recombinant LGG-pulsed BMDCs. These results reflected that an antigen 
threshold is required for the activation of T cells. The differential magnitude of T 
cell activation could be due to the differential amount of Blo t 5 expressed in these 
two recombinant lactobacilli.   
 
To our knowledge, this was the first study which described the in vitro 
immunological characterisation of two recombinant Lactobacillus strains with 
distinct adjuvant properties. With the use of pSIP412 expression vector, the results 
clearly demonstrated that high levels of Blo t 5 were expressed in the intracellular 
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compartment of in Lactobacillus plantarum NC8 and LGG than other expression 
systems. The in vitro data on DC-lactobacilli co-cultures revealed that 
Lactobacillus plantarum NC8 and LGG possess some differential modulatory 
effects on murine DCs, implying that these two Lactobacillus strains may exhibit 
significant differential intrinsic adjuvant properties in vivo. The in vivo 
immunomodulatory effects of recombinant Lactobacillus plantarum NC8 and 











The prevalence of house dust mite (HDM)-associated allergic diseases has 
alarmingly increased worldwide. HDM-associated allergic diseases are 
Th2-mediated inflammatory diseases that are well characterised by an imbalance 
of T helper-like immune responses with an exaggerated production of Th2 
cytokines such as Interleukin (IL)-4, IL-5 and IL-13 leading to the production of 
allergen-specific immunoglobulin (Ig)-E. The pathological roles of 
allergen-specific Th2 cells and Th2 cytokines in the allergic reactions have been 
documented in humans and mice (Lloyd CM, 2001; Galli SJ, 2008). Briefly, IL-4 
and IL-13 induce IgE class switching. IL-4 promotes Th2 cell differentiation 
whereas IL-5 is crucial for the activation and recruitment of eosinophils. IL-13 is a 
critical Th2 cytokine which mediates cellular responses relevant to asthma (Walter 
DM, 2001; Kuperman DA, 2002; Wills-Karps M, 2004). Current available 
treatments for allergy and asthma are mainly based on the pharmacological 
interventions such as treatment with antihistamines, glucocorticoids or β-agonists. 
However, the pharmacotherapeutic drugs are largely for symptomatic treatment of 
allergic diseases and patients suffering from chronic allergic diseases are required 




are the main health concerns. For example, glucocorticoids can result in decreased 
bone density in atopic children. New strategies, which provide specific and 
long-lasting protective effects by targeting and modulationg allergen- specific Th2 
immune responses, are therefore highly desirable for the prevention and treatment 
of allergic diseases. 
 
Dietary lactic acid bacteria (LAB) with GRAS status have been reported to exert 
beneficial health effects (Fuller R, 1989; Isolauri E, 2001; Mercenier A, 2003). 
The epidemiological studies have reported a difference in the gut microflora 
composition of allergic and healthy children, suggesting the possible role of 
Lactobacillus in the development of allergic diseases (Sepp E, 1997; Bjorksten B, 
1999; Bottcher MF, 2000). Recent experimental data indicates that some 
Lactobacillus strains inhibit antigen-specific IgE production, modulate T cell 
responses, as well as suppress the allergen-induced airway inflammation and 
airway hyper-reactivity (Murosaki S, 1998; Shida K, 1998; Kruisselbrink A, 2001; 
Forsythe P, 2007; Feleszko W, 2007; Hisbergues M, 2007). In addition, some 
clinical trials have highlighted the anti-allergic effects of some Lactobacillus 
strains (Kalliomaki M, 2001; Kalliomaki M, 2003; Rosenfeldt V, 2003; Rautava S, 
2005; Abrahamsson TR, 2007; Kukkonen K, 2007). To date, advanced genetic 
engineering has allowed the use of Lactobacillus for the development of an 
antigen-based oral vaccine. Few reports have demonstrated that recombinant 




(Kruisselbrink A, 2001; Daniel C, 2006; Charng YC, 2006; Rigaux P, 2009). 
Taken together, allergen-expressing recombinant lactobacilli offer a promising 
and safer mode of prevention and treatment for allergic diseases. 
 
As described in the chapter 3 of this thesis, recombinant Lactobacillus plantarum 
NC8 and recombinant LGG expressing Blo t 5 have been generated and evaluated 
by in vitro immunological studies. Protein quantification has revealed that high 
levels of Blo t 5 were expressed in the intracellular compartment of Lactobacillus 
plantarum NC8 and LGG. In addition, the in vitro data on DC-lactobacilli 
co-cultures have shown that Lactobacillus plantarum NC8 and LGG possess some 
differential modulatory effects on murine DCs, implying that these two 
Lactobacillus strains may exhibit differential intrinsic adjuvant properties in vivo. 
Therefore, it is hypothesised that these Blo t 5-expressing recombinant lactobacilli 
would probably be able to modulate DCs and lead to the induction of 
antigen-specific T cell responses that antagonise specific Th2 cell responses and 
allergic airway inflammation. The present study aims to study the immunogenicity 
and immunomodulatory effects of recombinant Lactobacillus plantarum NC8 and 
recombinant LGG expressing Blo t 5 in mouse allergy models. Firstly, the 
capacity of recombinant Lactobacillus plantarum NC8 and recombinant LGG to 
prime Blo t 5-specific immune responses in naïve mice is determined. Secondly, 
their prophylactic and therapeutic anti-allergic and anti-inflammatory effects are 





4.2.1 The immunogenicity of recombinant lactobacilli in vivo  
To investigate whether recombinant lactobacilli expressing Blo t 5 protein could 
prime both antibody and T cell responses against Blo t 5 in vivo, groups of four 
mice were orally fed with 1010 live recombinant LGG or recombinant 
Lactobacillus plantarum NC8 for 3 consecutive days for 3 weeks (Figure 4.1). 
PBS- and wildtype lactobacilli-fed mice were included as controls. Sera were 
collected weekly for antibody measurement by ELISA. Cells from spleen and 
mesenteric lymph nodes (MLN) were harvested for in vitro cell cultures. Culture 

































Figure 4.1 The experimental protocol I for the evaluation of in vivo 
immunogenicity of the Blo t 5 expressed in recombinant lactobacilli. Female 
C57BL/6 mice (n = 4) were orally fed with 200 μl of phosphate buffered saline 
(PBS) or 1010 colony formation units (cfu) of wildtype lactobacilli (wtLAB) or 
recombinant lactobacilli (rLAB) for three consecutive days per week over three 
weeks. The mice were sacrificed two days after the last feeding. Cells from 
mesenteric lymph nodes and spleens were harvested for in vitro cell cultures. Sera 




Group 1: 200 μl PBS / mouse 
Group 2: 1010 cfu wtLAB / mouse 
Group 3: 1010 cfu rLAB / mouse 
Cell Culture 




4.2.1.1 The immunogenicity of recombinant Lactobacillus plantarum NC8 
Mice fed with recombinant Lactobacillus plantarum NC8 showed higher levels of 
Blo t 5-specific IgG1 and IgG2c at day 11 or earlier up to day 18 (Figure 4.2). The 
level of Blo t 5-specific IgE in these mice were undetectable (data not shown). 
There was no detectable level of Blo t 5-specific antibody in wildtype 
Lactobacillus plantarum NC8- and PBS-fed mice. 
 
Interestingly, only Blo t 5-stimulated MLN cells from mice fed with recombinant 
Lactobacillus plantarum NC8 produced a significant level of TGF-β (Figure 
4.3A). The levels of IFN-γ in the culture supernatants were low in recombinant 
Lactobacillus plantarum NC8-fed mice and undetectable in wildtype 
Lactobacillus plantarum-fed mice as compared to that of the PBS-fed mice 
(Figure 4.3B). The levels of IL-5 and IL-10 were undetectable for all groups of 
mice. 
 
Upon Blo t 5 stimulation, splenocytes from mice fed with recombinant 
Lactobacillus plantarum NC8 produced higher levels of IFN-γ and IL-10 as 
compared to that of the wildtype Lactobacillus plantarum NC8-fed mice (Figure 
4.4B and 4.4C). The level of IL-10 was significantly higher in the splenic cultures 
of recombinant Lactobacillus plantarum NC8-fed mice than PBS-fed mice 
(Figure 4.4B). The levels of IL-5 production by the splenocytes were low in 




control groups (Figure 4.4A). Wildtype Lactobacillus plantarum NC8-fed mice 
showed higher level of IFN-γ and significant increase in the level of IL-10 as 
compared to the PBS-fed mice (Figure 4.4B and 4.4C). Notably, the level of 
TGF-β was significantly lower in the splenic cultures of wildtype Lactobacillus 
plantarum NC8-fed mice as compared to that of the recombinant Lactobacillus 





































Figure 4.2 Oral feeding of recombinant Lactobacillus plantarum NC8 
induced the production of Blo t 5-specific immunoglobulins in mice. Mice 
were orally fed with phosphate buffered saline (PBS, grey bar), wildtype 
Lactobacillus plantarum NC8 (wtLp, white bar) or recombinant Lactobacillus 
plantarum NC8 (rLp, black bar) as described in the Figure 4.1. The levels of Blo t 
5-specific IgG2c (A) and IgG1 (B) were determined by enzyme-linked 
immunosorbent assays (ELISA). The antibody levels were expressed as arbitrary 



























































Figure 4.3 Oral feeding of recombinant Lactobacillus plantarum NC8 
enhanced the production of TGF-β in mesenteric lymph node cultures. Mice 
were orally fed with phosphate buffered saline (PBS, grey bar), wildtype 
Lactobacillus plantarum NC8 (wtLp, white bar) or recombinant Lactobacillus 
plantarum NC8 (rLp, black bar) as described in the Figure 4.1. On day 18, cells 
from mesenteric lymph nodes were harvested and cultured with 10 µg/ml of Blo t 
5 in the presence of antigen presenting cells. Culture supernatants were collected 
on day 5 for the measurement of TGF-β (A) and IFN-γ (B) by enzyme-linked 
immunosorbent assays. Data are presented as mean ± standard error of mean. **: 











































Figure 4.4 Oral feeding of recombinant Lactobacillus plantarum NC8 
enhanced the production of cytokines in splenic cultures. Mice were orally fed 
with phosphate buffered saline (PBS, grey bar), wildtype Lactobacillus plantarum 
NC8 (wtLp, white bar) or recombinant Lactobacillus plantarum NC8 (rLp, black 
bar) as described in the Figure 4.1. On day 18, splenic cells were harvested and 
cultured with 10 µg/ml of Blo t 5. Culture supernatants were collected on day 5 
for the measurement of IL-5 (A), IL-10 (B), IFN-γ (C) and TGF-β (D) by 
enzyme-linked immunosorbent assays. Data are presented as mean ± standard 











































4.2.1.2 The immunogenicity of recombinant LGG 
Naïve mice fed with recombinant LGG produced Blo t 5-specific IgG2c at day 18 
(Figure 4.5). The levels of Blo t 5-specific IgE and IgG1 were undetectable in sera 
from all groups of mice (data not shown). 
 
Upon Blo t 5 stimulation, only MLN cells from mice fed with the recombinant 
LGG produced a significant level of TGF-β (Figure 4.6A). Recombinant LGG-fed 
mice induced higher IFN-γ production as compared to that of the control groups 
(Figure 4.6B). The levels of IL-5 and IL-10 were undetectable in MLN cell 
cultures for all groups of mice (data not shown). 
 
In the Blo t 5-stimulated splenic cultures, splenocytes from mice fed with 
recombinant LGG produced higher levels of IL-10, IFN-γ and TGF-β as compared 
to that of the control groups (Figure 4.7B, 4.7C and 4.7D). The levels of IL-5 
production by the splenocytes were low in recombinant LGG-fed mice and 



























Figure 4.5 Oral feeding of recombinant Lactobacillus rhamnosus GG 
induced the Blo t 5-specific IgG2c production in mice. Mice were orally fed 
with phosphate buffered saline (PBS, grey bar), wildtype Lactobacillus 
rhamnosus GG (wtLGG, white bar) or recombinant Lactobacillus rhamnosus GG 
(rLGG, black bar) as described in the Figure 4.1. The levels of Blo t 5-specific 
IgG2c was determined by the enzyme-linked immunosorbent assay (ELISA) and 
expressed as arbitrary ELISA units. Data are presented as mean ± standard error 
of mean. 
 





































Figure 4.6 Oral feeding of recombinant Lactobacillus rhamnosus GG 
enhanced the production of IFN-γ and TGF-β in mesenteric lymph node 
cultures. Mice were orally fed with phosphate buffered saline (PBS, grey bar), 
wildtype Lactobacillus rhamnosus GG (wtLGG, white bar) or recombinant 
Lactobacillus rhamnosus GG (rLGG, black bar) as described in the Figure 4.1. On 
day 18, cells from mesenteric lymph nodes were harvested and cultured with 10 
µg/ml of Blo t 5 in the presence of antigen presenting cells. Culture supernatants 
were collected on day 5 for the measurement of TGF-β (A) and IFN-γ (B) by 
enzyme-linked immunosorbent assays. Data are presented as mean ± standard 











































Figure 4.7 Oral feeding of recombinant Lactobacillus rhamnosus GG 
enhanced the production of cytokines in splenic cultures. Mice were orally fed 
with phosphate buffered saline (PBS, grey bar), wildtype Lactobacillus 
rhamnosus GG (wtLGG, white bar) or recombinant Lactobacillus rhamnosus GG 
(rLGG, black bar) as described in the Figure 4.1. On day 18, splenic cells were 
harvested and cultured with 10 µg/ml of Blo t 5. Culture supernatants were 
collected on day 5 for the measurement of IL-5 (A), IL-10 (B), IFN-γ (C) and 
TGF-β (D) by enzyme-linked immunosorbent assays. Data are presented as mean 













































4.2.2 The prophylactic anti-allergy effects of recombinant lactobacilli in a 
mouse allergy model 
The potential application of the recombinant Lactobacillus plantarum NC8 and 
recombinant LGG as oral vaccines for the prevention of allergic diseases was 
evaluated in vivo. The experimental approach is schematically shown in Figure 
4.8. Briefly, groups of four mice were orally fed with 1010 live recombinant 
lactobacilli for 3 consecutive days for the first 3 weeks. PBS- and wildtype 
lactobacilli-fed mice were served as controls. All mice were subsequently 
challenged by receiving intraperitoneal injections of Blo t 5 protein in alum at 
days 32 and 53, respectively. Sera were collected weekly for antibody 
measurement by ELISA. Two weeks after the last injection, all mice were 
sacrificed and cells from the MLN and spleens were harvested for in vitro cell 
cultures. Culture supernatants were collected for the measurement of IL-4, IL-5, 



























Figure 4.8 The experimental protocol II for the study of prophylactic effects 
of recombinant lactobacilli in the allergic murine model. Female C57BL/6 
mice (n = 4) were orally fed with 200 μl of phosphate buffered saline (PBS), 1010 
colony formation units (cfu) of wildtype lactobacilli (wtLAB) or recombinant 
lactobacilli (rLAB) for three consecutive days per week over three weeks. Sixteen 
days after the last feeding, all mice were intraperitoneally (i.p.) injected with 10 
μg of Blo t 5 in 200 μl of PBS containing 4 mg of alum. Three weeks later, mice 
were received the second intraperitoneal injection of 5 μg of Blo t 5 in 200 μl of 
PBS containing 4 mg of alum. All mice were sacrificed on day 67. Cells from 
mesenteric lymph nodes and spleen were harvested for in vitro cell cultures. Sera 




Blo t 5 + alum 
Oral Feeding 
Group 1: 200 μl PBS / mouse 
Group 2: 1010 cfu wtLAB / mouse 
Group 3: 1010 cfu rLAB / mouse 
Cell Culture 




4.2.2.1 The prophylactic effects of recombinant Lactobacillus plantarum 
NC8 
The Blo t 5-specific antibody production profiles in mice fed with recombinant 
Lactobacillus plantarum NC8 were shown in Figure 4.9. Notably, a week after the 
first sensitisation challenge of Blo t 5 protein, recombinant Lactobacillus 
plantarum NC8-fed mice showed a remarkable high-level production of Blo t 
5-specific IgG2c, the signature IgG subclass for the Th1 responses. These mice 
also produced some Blo t 5-specific IgG1, but only basal levels of Blo t 5-specific 
IgE were detected. Conversely, mice fed with PBS or wildtype LAB produced 
higher levels of Blo t 5- specific IgE, but low levels of specific IgG2c, upon the 
Blo t 5 sensitisation challenge.  
 
Upon Blo t 5 stimulation, MLN cells from recombinant Lactobacillus plantarum 
NC8-fed mice produced no detectable level of IL-4 (Figure 4.10A), lower levels 
of IL-10 (Figure 4.10B) as well as Th1 cytokine such as IFN-γ (Figure 4.10D) as 
compared to that of the control mice fed with PBS- or wildtype. Similar levels of 
IL-13 production were detected in MLN culture supernatants for all three groups 
(Figure 4.10C). Unlike mice fed with recombinant Lactobacillus plantarum NC8, 
mice fed with PBS or wildtype LAB showed no protection against Blo t 5 
sensitisation challenge as reflected by the increased production of Th2 cytokines 




mice (Figure 4.10). There was no detectable level of IL-5 produced by MLN cells 
from all three groups.  
 
Blo t 5-stimulated splenocytes from recombinant Lactobacillus plantarum 
NC8-fed mice produced significant levels of IL-13, IL-10 and IFN-γ (Figure 
4.11C, 11.1D and 4.11E), but no undetectable levels of IL-4 and IL-5 (Figure 
4.11A and 4.11B). On the other hand, Blo t 5-stimulated splenocytes from mice 
fed with PBS or wildtype LAB produced the Th2 signature cytokines such as IL-4, 
IL-5 and IL-13. Higher levels of IL-10 and IFN-γ were produced by the stimulated 































Figure 4.9  Oral feeding of recombinant Lactobacillus plantarum NC8 
suppressed the production of Blo t 5-specific IgE and induced the production 
of Blo t 5-specific IgG1 and IgG2c in mice. Mice were immunized as described 
in the Figure 4.8. Mice were orally fed with phosphate buffered saline (PBS, grey 
bar), wildtype Lactobacillus plantarum NC8 (wtLp, white bar) or recombinant 
Lactobacillus plantarum NC8 (rLp, black bar) followed by the challenge of Blo t 
5 with alum. Sera were collected weekly for the antibody measurement. The levels 
of Blo t 5-specific IgE (A), IgG2c (B) and IgG1 (C) were measured by 
enzyme-linked immunosorbent assays (ELISA) and expressed as arbitrary ELISA 
units. Data are presented as mean ± standard error of mean. *: p < 0.05 as 
compared to the PBS-fed group; **: p < 0.01 as compared to the PBS-fed group; #: 
p < 0.05 as compared to the wildtype Lactobacillus plantarum NC8-fed group; ##: 
p < 0.01 as compared to the wildtype Lactobacillus plantarum NC8-fed group. 
 



























































































Figure 4.10 The cytokine profile of mesenteric lymph node cultures from 
mice fed with recombinant Lactobacillus plantarum NC8. Mice were 
immunized as described in the Figure 4.8. Mice were orally fed with phosphate 
buffered saline (PBS, grey bar), wildtype Lactobacillus plantarum NC8 (wtLp, 
white bar) or recombinant Lactobacillus plantarum NC8 (rLp, black bar) followed 
by the challenge of Blo t 5 with alum. Two weeks later, cells from mesenteric 
lymph nodes were harvested and cultured with 10 µg/ml of Blo t 5 in the presence 
of antigen presenting cells. Culture supernatants were collected on day 3 for the 
measurement of IL-4 (A), IL-10 (B), IL-13 (C) and IFN-γ (D) by enzyme-linked 
immunosorbent assays. Data are presented as mean ± standard error of mean. **: 



























































Figure 4.11 The cytokine profile of splenocyte cultures from mice fed with 
recombinant Lactobacillus plantarum NC8. Mice were immunized as described 
in the Figure 4.8. Mice were orally fed with phosphate buffered saline (PBS, grey 
bar), wildtype Lactobacillus plantarum NC8 (wtLp, white bar) or recombinant 
Lactobacillus plantarum NC8 (rLp, black bar) followed by the challenge of Blo t 
5 with alum. Two weeks later, splenocytes were collected and cultured with 10 
µg/ml of Blo t 5. Culture supernatants were collected on day 3 for the 
measurement of IL-4 (A), IL-5 (B), IL-10 (C), IL-13 (D) and IFN-γ (E) by 
enzyme-linked immunosorbent assays. Data are presented as mean ± standard 



















































4.2.2.2 The prophylactic effects of recombinant LGG 
The Blo t 5-specific antibody production profiles in mice fed with the recombinant 
LGG-fed mice was shown in Figure 4.12. Differential levels of Blo t 5-specific 
IgE were detected in sera from all three groups of mice, but the levels of the Blo t 
5-specific IgE in recombinant LGG-fed mice were significantly lower than that in 
the control mice. Recombinant LGG-fed mice also produced higher levels of Blo t 
5-specific IgG2c and IgG1 than the control mice after the intraperitoneal 
challenge with Blo t 5 protein in alum.  
 
Interestingly, when the MLN cells from three groups of mice were stimulated with 
Blo t 5 protein, a significant reduction in IL-13 level was detected in the MLN 
cultures of the recombinant LGG-fed mice than that of the PBS- and wildtype 
LGG-fed mice (Figure 4.13). The levels of IL-4, IL-5, IL-10 and IFN-γ were 
undetectable for all groups.  
 
Blo t 5-stimulated splenocytes from recombinant LGG-fed mice also showed a 
significantly lower level of IL-13 production as compared to that of the PBS-fed 
mice (Figure 4.14B). The levels of IL-10 and IFN-γ produced by the splenic 
cultures of recombinant LGG-fed mice were found lower than that of the control 
mice (Figure 4.14A and 4.14C). Interestingly, as compared to the splenocytes 




produced higher levels of IL-10 and IFN-γ and a significantly reduced level of 








































Figure 4.12 Oral feeding of recombinant Lactobacillus rhamnosus GG 
suppressed the production of Blo t 5-specific IgE and induced the production 
of Blo t 5-specific IgG1 and IgG2c in mice. Mice were immunized as described 
in the Figure 4.8. Mice were orally fed with phosphate buffered saline (PBS, grey 
bar) or wildtype Lactobacillus rhamnosus GG (wtLGG, white bar) or recombinant 
Lactobacillus rhamnosus GG (rLGG, black bar) followed by the challenge of Blo 
t 5 with alum. Sera were collected weekly for the antibody measurement by 
enzyme-linked immunosorbent assays (ELISA). The levels of Blo t 5-specific IgE 
(A), IgG2c (B) and IgG1 (C) were measured and expressed as arbitrary ELISA 
















































































Figure 4.13 Oral feeding of recombinant Lactobacillus rhamnosus GG 
suppressed the IL-13 production in mesenteric lymph node cultures. Mice 
were immunized as described in the Figure 4.8. Mice were orally fed with 
phosphate buffered saline (PBS, grey bar), wildtype Lactobacillus rhamnosus GG 
(wtLGG, white bar) or recombinant Lactobacillus rhamnosus GG (rLGG, black 
bar) followed by the challenge of Blo t 5 with alum. Two weeks later, cells from 
mesenteric lymph nodes were harvested and cultured with 10 µg/ml of Blo t 5 in 
the presence of antigen presenting cells. Culture supernatants were collected on 
day 3 for the IL-13 measurement by the enzyme-linked immunosorbent assay. 

































Figure 4.14 The cytokine profile of splenocyte cultures from mice fed with 
recombinant Lactobacillus rhamnosus GG. Mice were immunized as described 
in the Figure 4.8. Mice were orally fed with phosphate buffered saline (PBS, grey 
bar), wildtype Lactobacillus rhamnosus GG (wtLGG, white bar) or recombinant 
Lactobacillus rhamnosus GG (rLGG, black bar) followed by the challenge of Blo 
t 5 with alum. Two weeks later, splenocytes were collected and cultured with 10 
µg/ml of Blo t 5. Culture supernatants were collected on day 3 for the 
measurement of IL-10 (A), IL-13 (B) and IFN-γ (C) by enzyme-linked 
immunosorbent assays. Data are presented as mean ± standard error of mean. *: p 






































4.2.3 The evaluation of the anti-inflammatory effects of recombinant 
lactobacilli in an allergic airway inflammation mouse model 
To determine whether the recombinant Lactobacillus plantarum NC8 and 
recombinant LGG could attenuate the allergen-induced allergic airway 
inflammation, mice sensitised by Blo t 5-specific Th2 cells were fed with two 
recombinant Lactobacillus strains. The protocol is schematically shown in Figure 
4.15. Briefly, groups of four mice were orally fed with 1010 live recombinant 
lactobacilli for 3 consecutive days throughout the duration of the experiment. 
PBS- and wildtype lactobacilli-fed mice served as controls. Mice were adoptively 
transferred with PBS or Blo t 5-specific Th2 cells via tail vein injection at day 3. 
All mice were intranasally challenged with Blo t 5 at day 4, 5, 6, 25, 26 and 27. At 
day 28, mice were sacrificed and bronchoalveolar lavage fluids (BALF) were 
collected for the analysis of infiltrating cells by differential cell count. 
 
The cell infiltrates in BALF were examined by the cytospin slide preparations 
stained with Liu stain. As compared to the mice adoptively transferred with Blo t 
5-specific T cells, PBS-fed mice which were adoptively transferred with PBS 
(PBS/PBS), showed lower total cell number in BALF (Figure 4.16A). The 
infiltrating cell types in BALF of PBS/PBS mice were predominantly 
macrophages and monocytes (Figure 4.16B). As compared to PBS/PBS group, 
decreased numbers of macrophages and monocytes and increased numbers of 




adoptively transferred Blo t 5-specific T cells (PBS/Bt5 cells). These data 
indicated that these mice (PBS/Bt5 cells) developed allergic airway inflammation 
upon the intranasal challenge of Blo t 5 protein. Notably, lower percentage of 
eosinophils and higher percentage of macrophages and monocytes were found in 
the airway of the recombinant LGG-fed mice (rLGG/Bt5 cells) after intranasal 
challenge with Blo t 5 protein as compared to the control group (PBS/Bt5 cells). 
Conversely, the percentage of eosinophils was higher in wildtype LGG-fed mice 
(wtLGG/Bt5 cells) as compared to the control group (PBS/Bt5 cells). The 
percentages of cell types in wildtype Lactobacillus plantarum NC8 (wtLp/Bt5 
cells) and recombinant Lactobacillus plantarum NC8 (rLp/Bt5 cells) were found 
similar to that of the control group (PBS/Bt5 cells). These findings suggested that 
recombinant LGG could confer some degree of protection against Th2 
sensitisation, resulting in the attenuation of the airway inflammation in 



























Figure 4.15 The experimental protocol III for the study of protective effects 
of recombinant lactobacilli in an allergic airway inflammation model. Female 
C57BL/6 mice (n = 4) were received 200μl of phosphate buffered saline (PBS), 
1010 colony formation units cfu wildtype lactobacilli or 1010 cfu recombinant 
lactobacilli for three consecutive days per week for four weeks. Both recombinant 
Lactobacillus plantarum NC8 and recombinant Lactobacillus rhamnosus GG 
strains were tested in this protocol. On day 3, a total of 2 × 106 of Blo t 5-specific 
Th2 cells in 150 μl of PBS was intravenously (i.v.) transferred into mice via the 
tail vein. Mice were intranasally (i.n.) challenged with 50 µg of Blo t 5 in 50 µl 
PBS for the next three consecutive days after the cell transfer. All mice were 
received intranasal challenge of Blo t 5 for three consecutive days from day 25 
onwards. Twenty-four hours later, mice were sacrificed. Bronchoalveolar lavage 
fluids (BALF) were collected for differential cell counts. 
 
Group Oral Feeding i.v. i.n.  
Group 1: PBS PBS Blo t 5 
Group 2: PBS Th2 cells Blo t 5 
Group 3: wildtype Lactobacillus plantarum NC8 Th2 cells Blo t 5 
Group 4: recombinant Lactobacillus plantarum NC8  Th2 cells Blo t 5 
Group 5: wildtype Lactobacillus rhamnosus GG Th2 cells Blo t 5 
Group 6: recombinant Lactobacillus rhamnosus GG   Th2 cells Blo t 5 
Collection of 
BALF 
Intranasal challenge (i.n.) 






200 μl PBS or 1010 cfu of lactobacilli 



















Figure 4.16 Oral feeding of recombinant Lactobacillus rhamnosus GG but 
not recombinant Lactobacillus plantarum NC8 reduced the allergic airway 
inflammation in lungs. Mice were immunized as described in the Figure 4.15. 
The total numbers of cellular infiltrates (A) and differential cell counts (B) in the 
bronchoalveolar lavage fluids of phosphate buffered saline (PBS, grey bar)-, 
wildtype Lactobacillus plantarum NC8 (white bar)-, recombinant Lactobacillus 
plantarum NC8 (black bar)-, wildtype Lactobacillus rhamnosus GG (horizontally 
hatched bar)- and recombinant Lactobacillus rhamnosus GG (dotted bar)-fed mice 
were shown. The percentages of macrophages/monocytes (mac/mono), 
lymphocytes (lym), neutrophils (neu) and eosinophils (eos) were derived from the 
number of each cell type divided with 500 counted cells examined at the 


























































In the present study, the immunogenicity of both recombinant Lactobacillus 
plantarum NC8 and recombinant LGG was first evaluated by feeding naive mice 
with these Blo t 5-expressing recombinant LAB. Blo t 5-specific B and T cell 
responses in these mice were examined by immunological analysis. These results 
showed that both strains of recombinant lactobacilli induced Blo t 5-specific 
antibodies. The levels of specific antibodies were detectable in sera from 
recombinant Lactobacillus plantarum NC8-fed mice as early as day four, whereas 
the production of specific antibody in recombinant LGG-fed mice was only 
detectable at day 18. As aforementioned, the amount of Blo t 5 expressed by 
recombinant LGG was about 2.5-fold lower than that of the recombinant 
Lactobacillus plantarum NC8 (Table 3.1). The differential kinetics of antibody 
responses might be attributable to the differential levels of Blo t 5 expressed in 
these recombinant lactobacilli. Notably, both strains of recombinant lactobacilli 
induced high levels of specific IgG2c, with relatively low levels of specific IgG1 
and no detectable level of specific IgE. These findings may suggest that the 
recombinant LAB preferentially primed Th1-skewed immunity in these mice.  
 
MLNs are the crucial checkpoint for the priming and induction of antigen-specific 
T cells and oral tolerance. Studies using adoptively transferred TCR-transgenic T 
cells demonstrated that the antigen recognition occurs in the MLNs within few 




of oral tolerance (Spahn TW, 2002). TGF-β-producing T helper 3 (Th3) cells can 
be isolated by repeated restimulation of MLN or splenic lymphocytes from mice 
fed with low doses of antigen (Miller A, 1992). These regulatory T cells probably 
have an important role in the IgA class switching (Mowat AM, 2003). Th3 cells 
are normally triggered in an antigen-specific manner, but the suppressive effects 
can be exerted in an antigen-non-specific fashion. They can also exert “by-stander 
suppression” when they encounter the fed antigen in target organ (Weiner HL, 
2001). In this study, the Blo t 5-stimulated MLN cells from recombinant 
lactobacilli-fed mice produced significantly higher levels of TGF-β with low 
levels of IFN-γ (Figure 4.3A&B and Figure 4.6A&B). These data suggested that 
recombinant lactobacilli-uploaded DCs could prime and induce TGF-β-producing 
antigen-specific Th3 cells in MLNs environment. Th3 cells are Foxp3+ CD4+ T 
cells that may play a role in T cell tolerance and suppression activity. Further 
studies are required to characterise the phenotype and function of these 
antigen-specific T cells found in MLNs.   
 
Upon Blo t 5 stimulation, splenocytes from recombinant lactobacilli-fed mice 
produced low levels (slightly above basal levels) of IL-5, IFN-γ and TGF-β, but 
the IL-10 production was more significant as compared to the controls. On the 
basis of the cytokine profiles, there was no distinctly clear subset of polarised T 
cells observed. However, the elevated IL-10 production by the splenocytes may 




production of IL-10. Tr1 cells are CD4+ Foxp3- IL-10-producing adaptive Treg 
cells. It has been suggested that the mechanism of the therapeutic effect of 
allergen-specific immunotherapy for allergy involved the induction of adaptive 
Treg cells, such as IL-10 secreting Tr1 cells (Bohle B, 2007; Meiler F, 2008). 
 
Taken together, the cytokine data derived from the Blo t 5-stimulated MLN and 
splenocytes cultures revealed that both recombinant Lactobacillus plantarum NC8 
and recombinant LGG were capable of inducing Blo t 5-specific T and B cell 
responses in the treated mice. In addition, the data also suggested that these 
recombinant lactobacilli may have the capability to prime the induction of Blo t 
5-specific Th3 and Tr1 in these mice. However, further studies are required to 
confirm these preliminary data.  
 
Next, the prophylactic anti-allergy effects of both recombinant Lactobacillus 
plantarum NC8 and recombinant LGG were examined in a murine allergy model. 
In this study, recombinant lactobacilli, wildtype lactobacilli or PBS-fed mice were 
challenged with Blo t 5 sensitisation by two intraperitoneal injections with Blo t 5 
protein in alum. The production of Blo t 5-specific antibodies in mice sera was 
examined by ELISA. The ELISA data revealed that all mice fed with recombinant 
lactobacilli showed attenuated production of Blo t 5-specific IgE accompanied by 
high-level production of Blo t 5-specific IgG2c. It is conceivable that the 




5-expressing recombinant lactobacilli and then greatly boosted by the 
intraperitoneal injections of Blo t 5 protein in alum. Blo t 5-specific IgG2c was 
about 2.5-fold lower in recombinant LGG-fed mice as compared to recombinant 
Lactobacillus plantarum NC8-fed mice. Again, this may be due to the fact that 
recombinant LGG produced lower amount of Blo t 5 protein resulting in a weaker 
priming of Blo t 5-specific immune responses. Since IgG2c is the signature 
antibody for Th1-skewed responses, the high levels of IgG2c is indicative of the 
strong Th1-skewed Blo t 5-specific T cell responses that mediated the suppression 
of Th2-mediated production of Blo t 5-specific IgE. The production of Blo t 
5-specific IgG1 which was remarkably elevated after the second injection of Blo t 
5 protein in alum was observed in these mice. Further studies are needed to 
elucidate the precise underlying reason for the differential antibody production 
profiles and their immunological implications.  
 
At the cellular level, Blo t 5-stimulated cells of MLNs and spleens from 
recombinant Lactobacillus plantarum NC8-fed mice showed suppression of IL-4 
and IL-5 but not IL-13 production as compared to that of the control mice (Figures 
4.10 and 4.11). Higher production of IFN-γ and IL-10 was found in the splenic 
cultures of recombinant Lactobacillus plantarum NC8-fed mice as compared to 
that of the PBS-fed mice. Taken together, the antibody and T cytokine production 
profiles may infer that recombinant Lactobacillus plantarum NC8 could 




suppression mediated by both IL-10 and IFN-γ produced by the T regulatory and 
Th1 cells induced by the recombinant Lactobacillus plantarum NC8.  
 
On the other hand, similar experiments conducted with recombinant and wildtype 
LGG yielded distinctively different cytokine production profiles by MLN cells 
and splenocytes from the treated mice. The IL-13 levels in both MLN and splenic 
cultures of recombinant LGG-fed mice were significantly attenuated as compared 
to the PBS-fed controls. In addition, the production of IL-10 and IFN-γ by the Blo 
t 5 stimulated splenocytes from recombinant LGG-fed mice was not upregulated. 
It appears that there was a general suppression of cytokine production by Blo t 
5-specific T cells.  Unlike the scenario seen in mice treated with recombinant 
Lactobacillus plantarum NC8, there was no evidence to support the possible 
induction of antigen-specific T-regulatory or Th1 cells in recombinant LGG-fed 
mice. Therefore, the underlying mechanism in the suppression of Th2 responses 
by the recombinant LGG is yet to be elucidated.  
  
Experimental asthma mouse model established using Blo t 5-specific Th2 cells 
was used to determine whether recombinant Lactobacillus plantarum NC8 and 
recombinant LGG could suppress the allergen-induced allergic airway 
inflammation. The results showed that only mice fed with recombinant LGG 
showed attenuated airway inflammation upon the intranasal challenge with Blo t 5 




into the allergen-challenged airways (Figure 4.16). It is worth noting that Blo t 
5-stimulated MLN and spleen cells from mice fed with recombinant LGG showed 
undetectable IL-4 and IL-5 as well as remarkable attenuation of IL-13 production 
(Figures 4.13 and 4.14B). This is an interesting observation in view of the fact that 
all these Th2 effector cytokines play crucial roles in allergic inflammation. IL-5 
enhances recruitment and survival of eosinophils in the airway. IL-13 is a potent 
effector cytokine that induces the central features of asthma, such as eosinophilia, 
mucus production, airway hyper-reactivity (Wills-Karp M, 1998; Kuperman DA, 
2002). The attenuation of IL-13 may be one of the mechanisms for the reduction 
of airway inflammation.   
 
Another possible mechanism underlying the anti-allergic inflammation could be 
linked to the possibility of recombinant LGG expressing Blo t 5 induced 
IL-10-producing tolerogenic DCs which eventually drive to the antigen-specific 
Treg cell development as discussed in chapter 3. It has been reported that 
genetically engineered DCs expressing IL-10 could induce antigen-specific 
tolerance in OVA-induced experimental model for airway allergy, probably 
through the action of OVA-specific CD4+CD25+Foxp3+ IL-10-producing 
regulatory T cells (Henry E, 2008). The precise mechanisms for the anti-allergic 
inflammation in the airway induced by the recombinant LGG should be a major 





In summary, these in vivo studies suggested that both the recombinant 
Lactobacillus plantarum NC8 and recombinant LGG, but not their wildtype 
counterparts, are potentially useful for the prevention of allergen sensitisation. 
However, it appears that recombinant LGG is more effective than recombinant 













Conclusion and Future Prospects 
 
 
Allergic asthma is one of the most important lung inflammatory diseases 
worldwide and sensitisation by Dermatophagoides pteronyssinus (Der p) and 
Blomia tropicalis (Blo t) allergens is the main trigger for the development of 
allergic asthma. To date, allergen-specific immunotherapy (SIT) represents the 
only aetiology treatment for allergic diseases, by providing an allergen-specific 
and long term protective immune response. The concept of using recombinant 
lactobacilli expressing allergens as oral vaccines for the prevention and treatment 
of allergic diseases has been explored in recent years. Several published results 
were promising but preliminary, thus further studies are necessary to dissect the 
underlying mechanisms for the optimisation of vaccine efficacy for clinical 
applications.  
 
Among others, two key factors such as the choice of Lactobacillus strain and the 
amount of antigen produced by the recombinant Lactobacillus strains are crucial 
in the design of a live vector for efficient oral vaccination. Lactobacillus 
rhamnosus GG is one of the best-studied probiotic bacteria for anti-allergy 
whereas Lactobacillus plantarum NC8 is a common Lactobacillus strain for 




chosen as the host strains for the expression of Blo t 5 major mite allergen using 
an inducible pSIP412 expression system. The results showed that both 
recombinant lactobacilli expressed high levels of Blo t 5 in their intracellular 
compartment. As dendritic cell (DC)-derived cytokines play the most important 
role in the T cell polarization towards Th1 or Th2 or Treg cell development, the 
immunomodulatory effects of the two recombinant lactobacilli on murine DCs 
were therefore examined by in vitro studies. Notably, both recombinant 
lactobacilli exhibited differential modulatory effects on the cytokine production by 
DCs. Recombinant Lactobacillus rhamnosus GG-pulsed DCs significantly 
induced higher levels of IL-10 and IL-12 production as compared to that of the 
recombinant Lactobacillus plantarum NC8-pulsed DCs. Both recombinant 
lactobacilli-pulsed dendritic cells effectively uptake recombinant lactobacilli, 
processed and presented Blo t 5 to Blo t 5-specific T cells and subsequently led to 
the activation of a Blo t 5-specific T cell line. These in vitro findings implied that 
recombinant lactobacilli possess their own distinct adjuvanicity, induce 
differential immunomodulatory effects on cytokine production by DCs and 
potentially able to drive the differential polarisation of Th1, Th2 or T regulatory 
subsets.   
 
The in vivo immunogenicity studies demonstrated that both recombinant 
Lactobacillus plantarum NC8 and recombinant Lactobacillus rhamnosus GG 




Th1-skewed IgG2c without any detectable Blo t 5-specific IgE priming. This 
study suggested the potential use of these recombinant lactobacilli for the oral 
priming of a protective anti-allergy immunity. Therefore, their respective 
prophylactic effects were further investigated in an allergy murine model. 
Interestingly, the findings clearly showed that both recombinant Lactobacillus 
strains but not wildtype Lactobacillus strains could downregulate the production 
of Blo t 5-specific IgE and upregulate the production of Blo t 5-specific IgG2c in 
Blo t 5-sensitised mice. Moreover, the oral administration of recombinant 
Lactobacillus strains led to the downregulation of Th2 cytokine production by 
mesenteric lymph node cells and splenocytes. Strikingly, a reduction of the 
eosinophils infiltration into BALF was shown in recombinant Lactobacillus 
rhamnosus GG-fed mice. These anti-inflammatory effects were not observed in 
recombinant Lactobacillus plantarum NC8-fed mice. Taken together, these 
findings suggested that both recombinant Lactobacillus strains could be potential 
promising candidates for the development of preventive oral vaccine for 
mite-allergy triggered allergic diseases. However, the recombinant Lactobacillus 
rhamnosus GG instead of the recombinant Lactobacillus plantarum NC8, appears 
to be a better candidate for the development of therapeutic oral vaccine for 
treatment of allergic inflammation associated with allergic asthma. It is 
noteworthy that the use of pSIP412 expression system in Lactobacillus rhamnosus 
GG as a host strain for Blo t 5 expression and the evaluation of the recombinant 




have not been reported. This study is probably the first of such studies in the field. 
However, the precise underlying mechanisms of the immunomodulatory effects of 
these recombinant lactobacilli remain to be further elucidated. 
 
Several aspects in this study require further extensive investigation. The 
optimisation in the immunisation protocol represents one of the key areas to be 
addressed. The optimised dosage of both recombinant lactobacilli required to 
prime protective anti-allergic immune responses by antigen-specific 
immunomodulation, has to be determined by further dose response in vivo studies. 
Moreover, the identification and characterisation of the T cell subsets are crucial 
for elucidating the underlying mechanisms that antagonise the Th2 immune 
responses. In vitro and in vivo studies targeting at the interactions of these 
recombinant lactobacilli with antigen presenting cells such as DCs, and other 
immune and non-immune cells in the gut environment are highly necessary to 
understand the various differential modes of action of these recombinant 
lactobacilli. In addition, the possible role of IL-10-producing DCs induced by 
recombinant Lactobacillus rhamnosus GG in the suppression of Th2 immune 
responses and airway inflammation needs further in-depth investigations by a 
combination of cellular and molecular approaches involving techniques such as 
flow cytometric analysis, real-time quantitative RT-PCR, adoptive cell transfer 
experiments and so forth. Studies using genetically modified mice such as 




Further information derived from all these studies will facilitate the development 
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Appendix 1: The cDNA sequence of Blomia tropicalis group 5 allergen 
 
1   atgaagttcg ccatcgttct tattgcctgc tttgccgctt cggttttggc tcaagagcac 
61  aagccaaaga aggatgattt ccgaaacgaa ttcgatcact tgttgatcga acaggcaaac 
121 catgctatcg aaaagggaga acatcaattg ctttacttgc aacaccaact cgacgaattg 
181 aatgaaaaca agagcaagga attgcaagag aaaatcattc gagaacttga tgttgtttgc  
241 gccatgatcg aaggagccca aggagctttg gaacgtgaat tgaagcgaac tgatcttaac 
301 attttggaac gattcaacta cgaagaggct caaactctca gcaagatctt gcttaaggat 
361 ttgaaggaaa ccgaacaaaa agtgaaggat attcaaaccc aataa 
 
 
Appendix 1. The cDNA sequence of Blomia tropicalis group 5 allergen (Blo t 
5). This nucleotide sequence is from the GenBank with accession no: U59102. 
The cDNA sequence of Blo t 5 contains an open reading frame of 405 base pairs 
that encoded for the Blo t 5 signal peptide (17 residues; 1-51) and the mature Blo t 













Appendix 2. The NMR Solution Structure of Blo t 5. (A) The primary sequence 
alignment of the Group 5 and the Group 21 allergens from the different mite 
species, viz. Blomia tropicalis, Lepidoglyphus destructor, Dermatophagoides 
farina, and D. pteronyssinus. The sequence identities and the conservative 
substitutions are shaded yellow and gray, respectively, and the percentage identity 
with respect to Blo t 5 is shown at the end. The numbers on the left and the right 
sides of the sequences are indicative of the residue numbering for the proteins 
encoded in the cDNA sequence deposited in the databases with the following 
accession numbers: Blo t 5, O96870; Der f 5, BAE45865; Der p 5, P14004; Lep d 
5, Q9U5P2; Der p 21, ABC73706; and Blo t 21, AY800348. The 17 residue leader 
peptide of Blo t 5 is boxed, and the residues of mature Blo t 5 are numbered in 
blue on the top along with the secondary structure. The critical residues of the 
mAb 4A7 epitope are located on surfaces I and II as indicated. (B) The NMR 
solution structure of Blo t 5 shown as an ensemble of 20 conformers overlaid with 
the backbone atoms of the helical residues Leu18–Asp113 on the lowest-energy 




Blo t 5. The three helices are numbered A, B, and C and are colored red, green, 
and purple, respectively. (D) Two orientations of the Blo t 5 surface charge 
distribution generated by a 180º flip along the y axis and colored with blue for 
positive charge and red for negative charge. 
 
(Adapted from Naik MT, Chang CF, Kuo IC, Kung CC, Yi FC, Chua KY, Huang 
TH. Roles of structure and structural dynamics in the antibody recognition of the 




Appendix 3: Culture media used for Lactococcus lactis MG 1363 
 




0.5% soya peptone 
0.5% meat digest 
0.25% yeast extract 
0.05% ascorbic acid 
0.025% magnesium sulfate 
1.9% disodium glycerophosphate 
 
GM17 broth 









20 mM MgCl2 













2.5 mM MgCl2 
2.5 mM CaCl2 
 
 166
Appendix 4: Culture media used for Lactobacillus strains 
 
Sterilize all media by autoclaving. 
 
MRS broth 
1 % peptone 
0.8 % meat extract 
0.4 % yeast extract 
2% glucose 
1 mL of monooleate (Tween 80) 
0.2% potassium phosphate, dibasic 
0.5 % sodium acetate, trihydrate 
0.2 % ammonium citrate, tribasic 
0.02 % magnesium sulphate, heptahydrate 




0.5 M sucrose 








Appendix 5: DNA sequence of the pSIP412 expression vector 
 
   1 GAATTCGGTA CCCCGGGTTC GAAGGCGCCA AGCTTCAAAT TACAGCACGT GTTGCTTTGA  
  61 TTGATAGCCA AAAAGCAGCA GTTGATAAAG CAATTACTGA TATTGCTGAA AAATTGTAAT  
 121 TTATAAATAA AAATCACCTT TTAGAGGTGG TTTTTTTATT TATAAATTAT TCGTTTGATT  
 181 TCGCTTTCGA TAGAACAATC AAAGCGAGAA TAAGGAAGAT AAATCCCATA AGGGCGGGAG  
 241 CAGAATGTCC GAGACTAATT CATGAGATCG ATTTTTTATT AAAACGTCTC AAAATCGTTT  
 301 CTGAGACGTT TTAGCGTTTA TTTCGTTTAG TTATCGGCAT AATCGTTAAA ACAGGCGTTA  
 361 TCGTAGCGTA AAAGCCCTTG AGCGTAGCGT GCTTTGCAGC GAAGATGTTG TCTGTTAGAT  
 421 TATGAAAGCC GATGACTGAA TGAAATAATA AGCGCAGCGT CCTTCTATTT CGGTTGGAGG  
 481 AGGCTCAAGG GAGTTTGAGG GAATGAAATT CCCTCATGGG TTTGATTTTA AAAATTGCTT  
 541 GCAATTTTGC CGAGCGGTAG CGCTGGAAAA ATTTTTGAAA AAAATTTGGA ATTTGGAAAA  
 601 AAATGGGGGG AAAGGAAGCG AATTTTGCTT CCGTACTACG ACCCCCCATT AAGTGCCGAG  
 661 TGCCAATTTT TGTGCCAAAA ACGCTCTATC CCAACTGGCT CAAGGGTTTG AGGGGTTTTT  
 721 CAATCGCCAA CGAATCGCCA ACGTTTTCGC CAACGTTTTT TATAAATCTA TATTTAAGTA  
 781 GCTTTATTGT TGTTTTTATG ATTACAAAGT GATACACTAA TTTTATAAAA TTATTTGATT  
 841 GGAGTTTTTT AAATGGTGAT TTCAGAATCG AAAAAAAGAG TTATGATTTC TCTGACAAAA  
 901 GAGCAAGATA AAAAATTAAC AGATATGGCG AAACAAAAAG GTTTTTCAAA ATCTGCGGTT  
 961 GCGGCGTTAG CTATAGAAGA ATATGCAAGA AAGGAATCAG AATAAAAAAA ATAAGCGAAA  
1021 GCTCGCGTTT TTAGAAGGAT ACGAGTTTTC GCTACTTGTT TTTGATAAGG TAATATATCA  
1081 TGGCTATTAA ATACTAAAGC TAGAAATTTT GGATTTTTAT TATATCCTGA CTCAATTCCT  
1141 AATGATTGGA AAGAAAAATT AGAGAGTTTG GGCGTATCTA TGGCTGTCAG TCCTTTACAC  
1201 GATATGGACG AAAAAAAAGA TAAAGATACA TGGAATAGTA GTGATGTTAT ACGAAATGGA  
1261 AAGCACTATA AAAAACCACA CTATCACGTT ATATATATTG CACGAAATCC TGTAACAATA  
1321 GAAAGCGTTA GGAACAAGAT TAAGCGAAAA TTGGGGAATA GTTCAGTTGC TCATGTTGAG  
1381 ATACTTGATT ATATCAAAGG TTCATATGAA TATTTGACTC ATGAATCAAA GGACGCTATT  
1441 GCTAAGAATA AACATATATA CGACAAAAAA GATATTTTGA ACATTAATGA TTTTGATATT  
1501 GACCGCTATA TAACACTTGA TGAAAGCCAA AAAAGAGAAT TGAAGAATTT ACTTTTAGAT  
1561 ATAGTGGATG ACTATAATTT GGTAAATACA AAAGATTTAA TGGCTTTTAT TCGCCTTAGG  
1621 GGAGCGGAGT TTGGAATTTT AAATACGAAT GATGTAAAAG ATATTGTTTC AACAAACTCT  
1681 AGCGCCTTTA GATTATGGTT TGAGGGCAAT TATCAGTGTG GATATAGAGC AAGTTATGCA  
1741 AAGGTTCTTG ATGCTGAAAC GGGGGAAATA AAATGACAAA CAAAGAAAAA GAGTTATTTG  
1801 CTGAAAATGA GGAATTAAAA AAAGAAATTA AGGACTTAAA AGAGCGTATT GAAAGATACA  
1861 GAGAAATGGA AGTTGAATTA AGTACAACAA TAGATTTATT GAGAGGAGGG ATTATTGAAT  
1921 AAATAAAAGC CCCCCTGACG AAAGTCGAAG GGGGCTTTTA TTTTGGTTTG ATGTTGCGAT  
1981 TAATAGCAAT ACGATTGCAA TAAACAAAAT GATCCCCTTA GAAGCAAACT TAAGAGTGTG  
2041 TTGATAGTGC ATTATCTTAA AATTTTGTAT AATAGGAATT GAAGTTAAAT TAGATGCTAA  
2101 AAATAGGAAT TGAAGTTAAA TTAGATGCTA AAAATTTGTA ATTAAGAAGG AGGGATTCGT  
2161 CATGTTGGTA TTCCAAATGC GTAATGTAGA TAAAACATCT ACTGTTTTGA AACAGACTAA  
2221 AAACAGTGAT TACGCAGATA AATAAATACG TTAGATTAAT TCCTACCAGT GACTAATCTT  
2281 ATGACTTTTT AAACAGATAA CTAAAATTAC AAACAAATCG TTTAACTTCA GGAGAGATTA  
2341 CATGAACAAA AATATAAATA TCTCAAACTT TTTAACGAGT GAAAAAGTAC TCAACCAAAT  
2401 AATAAAACAA TTGAATTTAA AAGAAACCGA TACCGTTTAC GAAATTGGAA CAGGTAAAGG  




2521 TCATCTATTC AACTTATCGT CAGAAAAATT AAAACTGAAT ACTCGTGTCA CTTTAATTCA  
2581 CCAAGATATT CTACAGTTTC AATTCCCTAA CAAACAGAGG TATAAAATTG TTGGGAATAT  
2641 TCCTTACAAT TTAAGCACAC AAATTATTAA AAAAGTGGTT TTTGAAAGCC GTGCGTCTGA  
2701 CATCTATCTG ACTGTTGAAG AAGGATTCTA CAAGCGTACC TTGGATATTC ACCGAACACT  
2761 AGGGTTGCTC TTGCACACTC AAGTCTCGAT TCAGCAATTG CTTAAGCTGC CAGCGGAATG  
2821 CTTTCATCCT AAACCAAAAG TAAACAGTGT CTTAATAAAA CTTACCCGCC ATACCACAGA  
2881 TGTTCCAGAT AAATATTGGA AGCTATATAA GTACTTTGTT TCAAAATGGG TCAATCGAGA  
2941 ATATCGTCAA CTGTTTACTA AAAATCAGTT TCGTCAAGCA ATGAAACACG CCAAAGTAAA  
3001 CAATTTAAGT ACCATTACTT ATGAGCAAGT ATTGTCTATT TTTAATAGTT ATCTATTATT  
3061 TAACGGGAGG AAATAATTCT ATGAGTCGCT TTTTTAAATT TGGAAAGTTA CACGTTACTA  
3121 AAGGGAATGG AGACCGGGGT CGACCCTTCA ATAGAGTTCT TAACGTTAAT CCGAAAAAAA  
3181 CTAACGTTAA TATTAAAAAA TAAGATCCGC TTGTGAATTA TGTATAATTT GATTAGACTA  
3241 AAGAATAGGA GAAAGTATGA TGATATTTAA AAAACTTTCT CGTTAAGATA GGTTGTTGGT  
3301 GAGCATGTTA TATACGGATG TATCGGTTTC CTTAATGCAA AATTTTGTTG CTATCTTATT  
3361 AATTTTTCTA TTATATAGAT ATATTCAAAG AAAGATAACA TTTAAACGGA TCATATTAGA  
3421 TATTTTAATA GCGATTATTT TTTCAATATT ATATCTGTTT ATTTCAGATG CGTCATTACT  
3481 TGTAATGGTA TTAATGCGAT TAGGGTGGCA TTTTCATCAA CAAAAAGAAA ATAAGATAAA  
3541 AACGACTGAT ACAGCTAATT TAATTCTAAT TATCGTGATC CAGTTATTGT TAGTTGCGGT  
3601 TGGGACTATT ATTAGTCAGT TTACCATATC GATTATCAAA AGTGATTTCA GCCAAAATAT  
3661 ATTGAACAAT AGTGCAACAG ATATAACTTT ATTAGGTATT TTCTTTGCTG TTTTATTTGA  
3721 CGGCTTGTTC TTTATATTAT TGAAGAATAA GCGGACTGAA TTACAACATT TAAATCAAGA  
3781 AATCATTGAA TTTTCGTTAG AAAAACAATA TTTTATATTT ATATTTATTT TATTTATAGT  
3841 AATAGAAATT ATTTTAGCAG TTGGGAATCT TCAAGGAGTA ACAGCCACGA TATTATTAAC  
3901 CATTATCATT ATTTTTTGTG TCCTTATCGG GATGACTTTT TGGCAAGTGA TGCTTTTTTT  
3961 GAAGGCTTAT TCGATTCGCC AAGAAGCCAA TGACCAATTG GTCCGGAATC AACAACTTCA  
4021 AGATTATCTA GTCAATATCG AACAGCAGTA CACCGAATTA CGGCGATTTA AGCATGATTA  
4081 TCAAAACATC TTATTATCGT TGGAGAGTTT TGCCGAAAAG GGCGATCAGC AACAGTTTAA  
4141 GGCGTATTAC CAAGAATTAT TAGCACAACG GCCAATTCAA AGTGAAATCC AAGGGGCAGT  
4201 CATTGCACAA CTCGACTACT TGAAAAATGA TCCTATTCGA GGATTAGTCA TTCAAAAGTT  
4261 TTTGGCAGCC AAACAGGCTG GTGTTACTTT AAAATTCGAA ATGACCGAAC CAATCGAATT  
4321 AGCAACCGCT AATCTATTAA CGGTTATTCG GATTATCGGT ATTTTATTAG ACAATGCGAT  
4381 TGAACAAGCC GTTCAAGAAA CCGATCAATT GGTGAGTTGT GCTTTCTTAC AATCTGATGG  
4441 TTTAATCGAA ATTACGATTG AAAATACGGC CAGTCAAGTT AAGAATCTCC AAGCATTTTC  
4501 AGAGTTAGGC TATTCAACGA AAGGCGCTGG TCGGGGGACT GGTTTAGCTA ATGTGCAGGA  
4561 TTTGATTGCC AAACAAACCA ATTTATTCTT AGAAACACAG ATTGAAAATA GAAAGTTACG  
4621 ACAGACATTG ATGATTACGG AGGAAACTTA ATTTGTATCC CGTTTATTTA TTAGAGGATG  
4681 ATTTACAGCA ACAAGCGATT TATCAGCAAA TTATCGCGAA TACGATTATG ATTAACGAAT  
4741 TTGCAATGAC TTTAACATGC GCTGCCAGTG ATACTGAGAC ATTGTTGGCG GCAATTAAGG  
4801 ATCAGCAACG AGGTTTATTC TTTTTGGATA TGGAAATTGA GGATAACCGC CAAGCCGGTT  
4861 TAGAAGTGGC AACTAAGATT CGGCAGATGA TGCCGTTTGC GCAAATTGTC TTCATTACAA  
4921 CCCACGAGGA ACTGACATTA TTAACGTTAG AACGAAAAAT AGCGCCTTTA GATTACATTC  
4981 TCAAGGACCA AACAATGGCT GAAATCAAAA GGCAATTGAT TGATGATCTA TTGTTAGCTG  
5041 AGAAGCAAAA CGAGGCGGCA GCGTATCACC GAGAAAATTT ATTTAGTTAT AAAATAGGTC  




5161 CGGGTCATAT TAATTTGTTA GCCGTTACCA GAAAGGTTAC TTTTCCAGGA AATTTAAATG  
5221 CGCTGGAAGC CCAATATCCA ATGCTCTTTC GGTGTGATAA AAGTTACTTA GTTAACCTAT  
5281 CTAATATTGC CAATTATGAC AGTAAAACAC GGAGTTTAAA ATTTGTAGAT GGCAGTGAGG  
5341 CAAAAGTCTC GTTCCGGAAA TCACGGGAAC TAGTGGCCAA ATTAAAACAA ATGATGTAGC  
5401 GCCTGCAGGC ACGCCAAATG ATCCCAGTAA AAAGCCACCC GCATGGCGGG TGGCTTTTTA  
5461 TTAGCCCTAG AAGGGCTTCC CACACGCATT TCAGCGCCTT AGTGCCTTAG TTTGTGAATC  
5521 ATAGGTGGTA TAGTCCCGAA ATACCCGTCT AAGGAATTGT CAGATAGGCC TAATGACTGG  
5581 CTTTTATAAT ATGAGATAAT GCCGACTGTA CTTTTTACAG TCGGTTTTCT AATGTCACTA  
5641 ACCTGCCCCG TTAGTTGAAG AAGGTTTTTA TATTACAGCT CCAGATCTAC CGGTTTAATT  
5701 TGAAAATTGA TATTAGCGTT TAACAGTTAA ATTAATACGT TAATAATTTT TTTGTCTTTA  
5761 AATAGGGATT TGAAGCATAA TGGTGTTATA GCGTACTTAG CTGGCCAGCA TATATGTATT  
5821 CTATAAAATA CTATTACAAG GAGATTTTAG CCATGGCTGT AAAACGTTTA ATTGAAACTT  
5881 TTGTTCCGGA AAATTATAAA ATTTTCCTTG ATATTGACCG TAAAACTAAG AAAATAAAAG  
5941 GTCAAGTGGC AATTACTGGG GAAGCAAAAG ATACTGTTGT TGCCTTTCAT GCCAAAGGAT  
6001 TACACTTCAA CAAAGTTCGC GCTTTTAGTG TTGATACAAA CTTCATTGAA AATGAAGAAG  
6061 ATGAAGAAAT TGTTGTTAAA ATTGGTGAAA CAGGGCGCGT GACTGTTTCA TTTGAATATG  
6121 AAGCCGAATT GACTGACAAC ATGATGGGAA TCTATCCTTC ATATTATGAA GTCAATGGTG  
6181 AAAAGAAAAT GCTAATTGGC ACACAGTTTG AAAGCCATTT TGCTCGCCAA GCTTTCCCAT  
6241 CTATTGATGA ACCAGAAGCG AAAGCAACTT TCGATTTGTC AGTAAAATTT GATGAAGAAG  
6301 AAGGCGACAT CATTGTTTCA AATATGCCAG AACTCTTGAA TATTAATGGA ATTCACGTTT  
6361 TTGAACGGAC AGTTAAAATG AGTTCTTACC TTTTGGCTTT TGTATTCGGT GAACTTCAAT  
6421 ATAAAAAAGG AAAAACAAAA TCTGGTGTTG AAGTAGGTGC CTTTGCAACG AAAGCTCATA  
6481 GTCAAGCAGC ACTTGATTTC CCACTTGATA TTGCTATTCG TTCAATCGAA TTTTACGAAG  
6541 ATTATTATCA AACACCCTAT CCACTTCCAC ACAGCTGGCA TATTGCCTTG CCTGACTTCT  
6601 CATCAGGAGC AATGGAAAAC TGGGGATGTA TCACTTATCG TGAAGTTTGC ATGTTGGTTG  
6661 ACCCTGAAAA TGCAACCATT CAAAGTAAAC AATATGTGGC AACAGTTATT GCCCATGAAT  
6721 TGGCTCACCA GTGGTTCGGT GACCTTGTAA CTATGCAATG GTGGGATGAT TTGTGGCTCA  
6781 ACGAATCATT CGCTAACAAC ATGGAATATG TTTGTATGGA TGCTTTGGAA CCAAGTTGGA  
6841 ACGTTTGGGA ATCATTCTCA ATTTCAGAAG CCAATATGGC ATTGAATCGT GATGCAACTG  
6901 ATGGAGTTCA ATCTGTCCAC GTTGAAGTAA CTCACCCAGA TGAAATTGGA ACACTTTTTG  
6961 ATCCAGCAAT CGTCTATGCT AAAGGTTCAC GCTTAATGGT TATGCTTCGT AAATGGCTCG  
7021 GAGATGAAGA CTTTGCTGCT GGCTTAGCCC TTTATTTCAA ACGCCATCAA TATGGAAATA  
7081 CAGTTGGAGA CAATCTTTGG GATGCCTTGG CTGAAGTTTC TGGAAAAGAT GTGGCAGCCT  
7141 TCATGCACTC ATGGGTTAAT CAACCGGGTT ACCCTGTCGT TACAGCAGAA GTCGTTGATG  
7201 ATACTTTGAT TTTGAGCCAA AAACAATTCT TTGTTGGTGA AGGTGTTGAC AAAGGACGTT  
7261 TGTGGAATGT TCCATTGAAT ACCAATTGGA CAGGGCTACC AGACTTGCTT TCTTCTGAAA  
7321 AAGTTGAAAT TCCAGGGTTT GCTGCTTTGA AAACTAAAAA CAATGGTAAA GCTCTCTTTT  
7381 TGAATGATGC AAATATGGCT CATTACATCA TTGATTATAA GGGTGCTTTA CTGACAGACC  
7441 TTCTTTCAGA AGTTGAATCT TTGGAGAATG TGACAAAATT CCAAATCTTG CAAGACCGTA  
7501 AATTGTTGGC TAAAGCAGGT GTGATTTCTT ATGCTGACGT TGTAAATATC TTGCCATCAT  
7561 TCACTAATGA AGAATCTTAC CTTGTTAATA CTGGTTTGAG TCAACTCATT AGTGAGTTGG  
7621 AACTTTTTGT TGATGAAGAT TCAGAAACTG AAAAAGCCTT CCAAAGCTTG GTAGGAAAAC  
7681 TTTTTGCTAA AAATTATGCT CGTTTGGGTT GGGATAAAGT TGCTGGTGAA TCTGCTGGGG  




7801 AAACAAAAGC TAGCCAAATT TTTGCAACAC ATAAAGAAAA TTTAGCAAGT ATTCCAGCTG  
7861 ATATTCGTCC AATTGTTTTG AACAATGAAA TCAAAACAAC TAACTCGGCT GAATTGGTTA  
7921 AAACTTATCG TGAAACTTAT ATCAAAACAA GCCTCCAAGA ATTCAAACGT GAACTTGAAG  
7981 GGGCAGTTGC TTTGATTAAA GATGAAAAAG TTATTGCTGA ATTACTTGAA AGCTTCAAAA  
8041 ATGCCGATAT TGTTAAACCA CAAGATATTG CTTTCTCTTG GTTCTATCTT TTGCGCAATG  
8101 ATTTTTCACA AGATGCGGCA TGGGCTTGGG AAAAAGCAAA TTGGGCTTTC CTTGAAGAAA  
8161 AATTGGGTGG TGATATGAGT TATGACAAAT TTGTCATCTA TCCAGGGAAT ACTTTCAAAA  
8221 CTGCTGATAA ATTAGCGGAA TATAAAGCTT TCTTTGAACC AAAATTAGAA AACCAAGGCT  
8281 TGAAACGTTC AATTGAAATG GCAATTAAAC AAATTACAGC ACGTGTTGCT TTGATTGATA  
8341 GCCAAAAAGC AGCAGTTGAT AAAGCAATTA CTGATATTGC TGAAAAATTG TAATCTAGAC  
8401 TCGAG       
 
Appendix 5. DNA sequence of the pSIP412 expression vector (8405 bp). 
Sequence coding for MCS: 1-30; pepN terminator: 40-260; pSH71 replicon: 
260-2010; ermB: 2010-3140; sppKR regulatory genes, 3140-5410; double 
terminator, 5410-5690; Porfx promoter: 5690-5852; pepN reporter gene (2553 bp): 
5853-8405. NcoI (CCATGG; 5851-5856) and XhoI (CTCGAG; 8399-8405) 














Appendix 6. Skeletons of mouse right hind limb. The bone marrow cells were 
flushed out from the femora and tibiae of the hind limbs as the source of cells to 
derive dendritic cells in vitro. (Adapted from Margaret J. Cook, The Anatomy of 
the Laboratory Mouse, 1965). 
